WO2021145655A1 - 신규한 피라졸 유도체 - Google Patents
신규한 피라졸 유도체 Download PDFInfo
- Publication number
- WO2021145655A1 WO2021145655A1 PCT/KR2021/000425 KR2021000425W WO2021145655A1 WO 2021145655 A1 WO2021145655 A1 WO 2021145655A1 KR 2021000425 W KR2021000425 W KR 2021000425W WO 2021145655 A1 WO2021145655 A1 WO 2021145655A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pyridin
- substituted
- tetrahydro
- pyrazolo
- unsubstituted
- Prior art date
Links
- 150000003217 pyrazoles Chemical class 0.000 title description 7
- -1 pyrazole derivative compound Chemical class 0.000 claims abstract description 119
- 150000003839 salts Chemical class 0.000 claims abstract description 37
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
- 150000001875 compounds Chemical class 0.000 claims description 131
- 125000001424 substituent group Chemical group 0.000 claims description 78
- 229910052736 halogen Inorganic materials 0.000 claims description 69
- 150000002367 halogens Chemical class 0.000 claims description 64
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 55
- 150000001412 amines Chemical class 0.000 claims description 55
- 229910052805 deuterium Inorganic materials 0.000 claims description 55
- 125000001188 haloalkyl group Chemical group 0.000 claims description 54
- 206010016654 Fibrosis Diseases 0.000 claims description 49
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 47
- 125000000217 alkyl group Chemical group 0.000 claims description 45
- 229910052739 hydrogen Inorganic materials 0.000 claims description 41
- 239000001257 hydrogen Substances 0.000 claims description 41
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 38
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 38
- 125000003545 alkoxy group Chemical group 0.000 claims description 37
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 claims description 35
- 201000010099 disease Diseases 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 29
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 27
- 125000003118 aryl group Chemical group 0.000 claims description 27
- 229910052760 oxygen Inorganic materials 0.000 claims description 27
- 239000012453 solvate Substances 0.000 claims description 27
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims description 26
- 125000005842 heteroatom Chemical group 0.000 claims description 26
- 206010028980 Neoplasm Diseases 0.000 claims description 25
- 229910052717 sulfur Inorganic materials 0.000 claims description 25
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 24
- 150000002431 hydrogen Chemical class 0.000 claims description 24
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 24
- 230000036542 oxidative stress Effects 0.000 claims description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 21
- 201000011510 cancer Diseases 0.000 claims description 21
- 208000018737 Parkinson disease Diseases 0.000 claims description 18
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 17
- 125000001072 heteroaryl group Chemical group 0.000 claims description 17
- 230000007882 cirrhosis Effects 0.000 claims description 16
- 125000000732 arylene group Chemical group 0.000 claims description 15
- 229910052757 nitrogen Inorganic materials 0.000 claims description 15
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 125000000172 C5-C10 aryl group Chemical group 0.000 claims description 10
- 125000002947 alkylene group Chemical group 0.000 claims description 10
- 208000027866 inflammatory disease Diseases 0.000 claims description 8
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 7
- 125000006833 (C1-C5) alkylene group Chemical group 0.000 claims description 7
- 235000011054 acetic acid Nutrition 0.000 claims description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- NKUSQRCWUADRSC-UHFFFAOYSA-N C1=C(C=C(N=C1C)N1C(=C2C(=N1)CCN(C2)CC1=CC=CC=C1)O)C(F)(F)F Chemical compound C1=C(C=C(N=C1C)N1C(=C2C(=N1)CCN(C2)CC1=CC=CC=C1)O)C(F)(F)F NKUSQRCWUADRSC-UHFFFAOYSA-N 0.000 claims description 6
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 6
- ZAXZRHNHSLTQHT-UHFFFAOYSA-N N1(C(=C2C(=N1)CCN(C2)CC1=CC(C(F)(F)F)=CC=C1)O)C1=NC=C(C(F)(F)F)C=C1 Chemical compound N1(C(=C2C(=N1)CCN(C2)CC1=CC(C(F)(F)F)=CC=C1)O)C1=NC=C(C(F)(F)F)C=C1 ZAXZRHNHSLTQHT-UHFFFAOYSA-N 0.000 claims description 6
- GSUWCTYZHTUNEF-UHFFFAOYSA-N OC1=C(CN(CC2=CC=CC=C2)CC2)C2=NN1C1=NC=CC2=C1C=CS2 Chemical compound OC1=C(CN(CC2=CC=CC=C2)CC2)C2=NN1C1=NC=CC2=C1C=CS2 GSUWCTYZHTUNEF-UHFFFAOYSA-N 0.000 claims description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 6
- YSYNSHQXHVWDKR-UHFFFAOYSA-N C12=C(N(N=C2CN(CC1)C(=O)C1=CC=CC=C1)C1=NC=CC=C1)O Chemical compound C12=C(N(N=C2CN(CC1)C(=O)C1=CC=CC=C1)C1=NC=CC=C1)O YSYNSHQXHVWDKR-UHFFFAOYSA-N 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 5
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 5
- KILLWHKMJCRMAC-UHFFFAOYSA-N N1=C2C(=C(N1C1=NC=CC=C1)O)CCN(C2)CC1=CC=CC=C1 Chemical compound N1=C2C(=C(N1C1=NC=CC=C1)O)CCN(C2)CC1=CC=CC=C1 KILLWHKMJCRMAC-UHFFFAOYSA-N 0.000 claims description 5
- MZSGPSXKNSQTLI-UHFFFAOYSA-N N1=C2C(=C(N1C1=NC=CC=C1)O)CCN(C2)CCC Chemical compound N1=C2C(=C(N1C1=NC=CC=C1)O)CCN(C2)CCC MZSGPSXKNSQTLI-UHFFFAOYSA-N 0.000 claims description 5
- JWQSQJVGIWFVGT-UHFFFAOYSA-N OC1=C2CCCCC2=NN1C1=CC=CC=N1 Chemical compound OC1=C2CCCCC2=NN1C1=CC=CC=N1 JWQSQJVGIWFVGT-UHFFFAOYSA-N 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 5
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- WITCLCSMLAFXFZ-UHFFFAOYSA-N C(=O)(N1CCC=2C(=NN(C=2O)C2=NC=CC=C2)C1)CCC Chemical compound C(=O)(N1CCC=2C(=NN(C=2O)C2=NC=CC=C2)C1)CCC WITCLCSMLAFXFZ-UHFFFAOYSA-N 0.000 claims description 4
- BYUWFYRAFZTNEK-UHFFFAOYSA-N C(=O)(N1CCC=2C(=NN(C=2O)C2=NC=CC=C2)C1)NCC1=CC=CO1 Chemical compound C(=O)(N1CCC=2C(=NN(C=2O)C2=NC=CC=C2)C1)NCC1=CC=CO1 BYUWFYRAFZTNEK-UHFFFAOYSA-N 0.000 claims description 4
- VCGNYEMUVCTDMI-UHFFFAOYSA-N C(=O)(N1CCC=2C(=NN(C=2O)C2=NC=CC=C2)C1)OCC Chemical compound C(=O)(N1CCC=2C(=NN(C=2O)C2=NC=CC=C2)C1)OCC VCGNYEMUVCTDMI-UHFFFAOYSA-N 0.000 claims description 4
- VJUXTJRSTBILIT-UHFFFAOYSA-N C(=O)(N1CCC=2C(=NN(C=2O)C2=NC=CC=C2)C1)OCC1=CC=C(N(=O)=O)C=C1 Chemical compound C(=O)(N1CCC=2C(=NN(C=2O)C2=NC=CC=C2)C1)OCC1=CC=C(N(=O)=O)C=C1 VJUXTJRSTBILIT-UHFFFAOYSA-N 0.000 claims description 4
- WQCRKQQYLXDCTL-UHFFFAOYSA-N C(F)(F)(F)C1=CN=C(N2C(=C3C(CCCC3)=N2)O)C=C1 Chemical compound C(F)(F)(F)C1=CN=C(N2C(=C3C(CCCC3)=N2)O)C=C1 WQCRKQQYLXDCTL-UHFFFAOYSA-N 0.000 claims description 4
- IXCPBTYIBHUMRO-UHFFFAOYSA-N C1(O)=C2CCN(CC2=NN1C1=CC=CC=N1)C(=O)NCC1=CC=C(F)C=C1 Chemical compound C1(O)=C2CCN(CC2=NN1C1=CC=CC=N1)C(=O)NCC1=CC=C(F)C=C1 IXCPBTYIBHUMRO-UHFFFAOYSA-N 0.000 claims description 4
- GXUCGTRSUSBION-UHFFFAOYSA-N C12=C(N(N=C2CN(CC1)C(=O)OCC1=CC=CC=C1)C1=NC=CC=C1)O Chemical compound C12=C(N(N=C2CN(CC1)C(=O)OCC1=CC=CC=C1)C1=NC=CC=C1)O GXUCGTRSUSBION-UHFFFAOYSA-N 0.000 claims description 4
- JZDZCWJTVMXQKD-UHFFFAOYSA-N C12=C(N(N=C2CN(CC1)CC1=CC=CC=C1)C1=C(OC)C=CC=C1)O Chemical compound C12=C(N(N=C2CN(CC1)CC1=CC=CC=C1)C1=C(OC)C=CC=C1)O JZDZCWJTVMXQKD-UHFFFAOYSA-N 0.000 claims description 4
- GXCITHNQWIUUEF-UHFFFAOYSA-N C12=C(N(N=C2CN(CC1)S(=O)(=O)C)C1=NC=CC=C1)O Chemical compound C12=C(N(N=C2CN(CC1)S(=O)(=O)C)C1=NC=CC=C1)O GXCITHNQWIUUEF-UHFFFAOYSA-N 0.000 claims description 4
- MNFOHVNHOLHACS-UHFFFAOYSA-N C1=C(NC(=O)N2CCC=3C(=NN(C=3O)C3=NC=CC=C3)C2)C=CC(F)=C1 Chemical compound C1=C(NC(=O)N2CCC=3C(=NN(C=3O)C3=NC=CC=C3)C2)C=CC(F)=C1 MNFOHVNHOLHACS-UHFFFAOYSA-N 0.000 claims description 4
- GSJDUPXSCUFGKU-UHFFFAOYSA-N C1=CC=CC=C1S(=O)(=O)N1CC=2C(CC1)=C(O)N(N=2)C1=NC=CC=C1 Chemical compound C1=CC=CC=C1S(=O)(=O)N1CC=2C(CC1)=C(O)N(N=2)C1=NC=CC=C1 GSJDUPXSCUFGKU-UHFFFAOYSA-N 0.000 claims description 4
- MQOQKWJUZSJAGG-UHFFFAOYSA-N C1C(NC(=O)N2CCC=3C(=NN(C=3O)C3=NC=CC=C3)C2)CCCC1 Chemical compound C1C(NC(=O)N2CCC=3C(=NN(C=3O)C3=NC=CC=C3)C2)CCCC1 MQOQKWJUZSJAGG-UHFFFAOYSA-N 0.000 claims description 4
- XFNRMQGDLJKKPK-UHFFFAOYSA-N C1C=2C(CN(C1)C(=O)C)=NN(C=2O)C1=CC=CC=N1 Chemical compound C1C=2C(CN(C1)C(=O)C)=NN(C=2O)C1=CC=CC=N1 XFNRMQGDLJKKPK-UHFFFAOYSA-N 0.000 claims description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 4
- 208000023105 Huntington disease Diseases 0.000 claims description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
- MNFGUWIEALDYDI-UHFFFAOYSA-N N1=C(C=C(C=C1N1C(=C2CCN(CC2=N1)CC1=CC=CC=C1)O)C(F)(F)F)C Chemical compound N1=C(C=C(C=C1N1C(=C2CCN(CC2=N1)CC1=CC=CC=C1)O)C(F)(F)F)C MNFGUWIEALDYDI-UHFFFAOYSA-N 0.000 claims description 4
- MSSVNXXJRKBSJB-UHFFFAOYSA-N N1=C2C(=C(N1C1=NC=C(C(F)(F)F)C=C1)O)CCN(C2)CC1=CC=CC=C1 Chemical compound N1=C2C(=C(N1C1=NC=C(C(F)(F)F)C=C1)O)CCN(C2)CC1=CC=CC=C1 MSSVNXXJRKBSJB-UHFFFAOYSA-N 0.000 claims description 4
- VYRIKGKYZGPDCI-UHFFFAOYSA-N N1=C2C(=C(N1C1=NC=CC=C1)O)CCN(C2)CC Chemical compound N1=C2C(=C(N1C1=NC=CC=C1)O)CCN(C2)CC VYRIKGKYZGPDCI-UHFFFAOYSA-N 0.000 claims description 4
- XTZHLCLZTLBTHT-UHFFFAOYSA-N N1=C2C(=C(N1C1=NC=CC=C1)O)CCN(C2)CC1=CC(F)=CC(F)=C1 Chemical compound N1=C2C(=C(N1C1=NC=CC=C1)O)CCN(C2)CC1=CC(F)=CC(F)=C1 XTZHLCLZTLBTHT-UHFFFAOYSA-N 0.000 claims description 4
- ILUOCMWSDDTFPW-UHFFFAOYSA-N N1=C2C(=C(N1C1=NC=CC=C1)O)CCN(C2)CC1=CC=C(C#N)C=C1 Chemical compound N1=C2C(=C(N1C1=NC=CC=C1)O)CCN(C2)CC1=CC=C(C#N)C=C1 ILUOCMWSDDTFPW-UHFFFAOYSA-N 0.000 claims description 4
- CBCBVHYLYFIGIM-UHFFFAOYSA-N N1=C2C(=C(N1C1=NC=CC=C1)O)CCN(C2)CC1=CC=C(C)C=C1 Chemical compound N1=C2C(=C(N1C1=NC=CC=C1)O)CCN(C2)CC1=CC=C(C)C=C1 CBCBVHYLYFIGIM-UHFFFAOYSA-N 0.000 claims description 4
- TUPHKAJUJPNHOT-UHFFFAOYSA-N N1=C2C(=C(N1C1=NC=CC=C1)O)CCN(C2)CC1=CC=C(N(C)C)C=C1 Chemical compound N1=C2C(=C(N1C1=NC=CC=C1)O)CCN(C2)CC1=CC=C(N(C)C)C=C1 TUPHKAJUJPNHOT-UHFFFAOYSA-N 0.000 claims description 4
- FKGAAGFVRGDLNX-UHFFFAOYSA-N N1=C2C(=C(N1C1=NC=CC=C1)O)CCN(C2)CC1=CC=C2C=CC=CC2=C1 Chemical compound N1=C2C(=C(N1C1=NC=CC=C1)O)CCN(C2)CC1=CC=C2C=CC=CC2=C1 FKGAAGFVRGDLNX-UHFFFAOYSA-N 0.000 claims description 4
- LOAABYORSUVAHU-UHFFFAOYSA-N N1=C2C(=C(N1C1=NC=CC=C1)OC)CCN(C2)CC1=CC=CC=C1 Chemical compound N1=C2C(=C(N1C1=NC=CC=C1)OC)CCN(C2)CC1=CC=CC=C1 LOAABYORSUVAHU-UHFFFAOYSA-N 0.000 claims description 4
- SOZFPLYNSXBWCG-UHFFFAOYSA-N OC1=C(CCN(C2)C(NCCC(C=C3)=CC=C3Cl)=O)C2=NN1C1=NC=CC=C1 Chemical compound OC1=C(CCN(C2)C(NCCC(C=C3)=CC=C3Cl)=O)C2=NN1C1=NC=CC=C1 SOZFPLYNSXBWCG-UHFFFAOYSA-N 0.000 claims description 4
- YDNMHBQSUAFDMH-UHFFFAOYSA-N OC1=C(CCN(CC2=CC=CC=C2)C2)C2=NN1C(C=C1)=NC=C1Cl Chemical compound OC1=C(CCN(CC2=CC=CC=C2)C2)C2=NN1C(C=C1)=NC=C1Cl YDNMHBQSUAFDMH-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- 208000031472 Retinal fibrosis Diseases 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 235000015165 citric acid Nutrition 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 208000002780 macular degeneration Diseases 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 239000011975 tartaric acid Substances 0.000 claims description 4
- 235000002906 tartaric acid Nutrition 0.000 claims description 4
- SJBBPAKEKIRAJB-UHFFFAOYSA-N C12=C(N(N=C2CN(CC1)CC1=CC=CC=C1)C1=NC=CC2=C1C=CS2)O Chemical compound C12=C(N(N=C2CN(CC1)CC1=CC=CC=C1)C1=NC=CC2=C1C=CS2)O SJBBPAKEKIRAJB-UHFFFAOYSA-N 0.000 claims description 3
- SRZNAXULLAETED-UHFFFAOYSA-N C1=C(C(=NC=C1)N1N=C2C(=C1O)CCN(C2)CC1=CC=CC=C1)F Chemical compound C1=C(C(=NC=C1)N1N=C2C(=C1O)CCN(C2)CC1=CC=CC=C1)F SRZNAXULLAETED-UHFFFAOYSA-N 0.000 claims description 3
- TWADNBBVUWGKNE-UHFFFAOYSA-N C1=C(N2C(=C3C(CN(C(=O)C4=CC(=C(C)C=C4F)N4C=C(C5CC5)N=C4)CC3)=N2)O)N=CC=C1 Chemical compound C1=C(N2C(=C3C(CN(C(=O)C4=CC(=C(C)C=C4F)N4C=C(C5CC5)N=C4)CC3)=N2)O)N=CC=C1 TWADNBBVUWGKNE-UHFFFAOYSA-N 0.000 claims description 3
- DHTRTUWWRMHOSP-UHFFFAOYSA-N C1=CC2=CC(S(=O)(=O)N3CCC=4C(=NN(C=4O)C4=NC=CC=C4)C3)=CC=C2C=C1 Chemical compound C1=CC2=CC(S(=O)(=O)N3CCC=4C(=NN(C=4O)C4=NC=CC=C4)C3)=CC=C2C=C1 DHTRTUWWRMHOSP-UHFFFAOYSA-N 0.000 claims description 3
- OQDFCIJZMYHYGV-UHFFFAOYSA-N C1=CC=C(CN2CCC=3C(C2)=C(O)N(N=3)C2=C(F)C=CC=N2)C=C1 Chemical compound C1=CC=C(CN2CCC=3C(C2)=C(O)N(N=3)C2=C(F)C=CC=N2)C=C1 OQDFCIJZMYHYGV-UHFFFAOYSA-N 0.000 claims description 3
- JAZCXMPBBIHTCQ-UHFFFAOYSA-N C1=CC=C(CN2CCC=3C(C2)=C(O)N(N=3)C2=NC=CC=C2)C=C1 Chemical compound C1=CC=C(CN2CCC=3C(C2)=C(O)N(N=3)C2=NC=CC=C2)C=C1 JAZCXMPBBIHTCQ-UHFFFAOYSA-N 0.000 claims description 3
- NLJJDOMYJDRGCE-UHFFFAOYSA-N C1=CC=C2C(=C1)C=C(CN1CCC=3C(C1)=C(O)N(N=3)C1=NC=CC=C1)C=C2 Chemical compound C1=CC=C2C(=C1)C=C(CN1CCC=3C(C1)=C(O)N(N=3)C1=NC=CC=C1)C=C2 NLJJDOMYJDRGCE-UHFFFAOYSA-N 0.000 claims description 3
- NUFNBCLJPQXZPY-UHFFFAOYSA-N C1=CC=CC(=C1)CN1CCC=2C(C1)=C(O)N(N=2)C1=CC=C(C(=O)O)C=C1 Chemical compound C1=CC=CC(=C1)CN1CCC=2C(C1)=C(O)N(N=2)C1=CC=C(C(=O)O)C=C1 NUFNBCLJPQXZPY-UHFFFAOYSA-N 0.000 claims description 3
- YZANXSRCJWOOLT-UHFFFAOYSA-N C1=CC=CC(=C1)CN1CCC=2C(C1)=C(O)N(N=2)C1=CC=CC=C1 Chemical compound C1=CC=CC(=C1)CN1CCC=2C(C1)=C(O)N(N=2)C1=CC=CC=C1 YZANXSRCJWOOLT-UHFFFAOYSA-N 0.000 claims description 3
- PTYSBGVFDLRCKC-UHFFFAOYSA-N C1=CC=CC(=C1)CN1CCC=2C(C1)=C(O)N(N=2)C1=NC=C(C=C1)C#N Chemical compound C1=CC=CC(=C1)CN1CCC=2C(C1)=C(O)N(N=2)C1=NC=C(C=C1)C#N PTYSBGVFDLRCKC-UHFFFAOYSA-N 0.000 claims description 3
- YWKZHOPRTUURMY-UHFFFAOYSA-N N#CC1=CC=C(CN(CCC2=NN3C4=NC=C(C(F)(F)F)C=C4)CC2=C3O)C=C1 Chemical compound N#CC1=CC=C(CN(CCC2=NN3C4=NC=C(C(F)(F)F)C=C4)CC2=C3O)C=C1 YWKZHOPRTUURMY-UHFFFAOYSA-N 0.000 claims description 3
- RJZWKQKWPZFGGD-UHFFFAOYSA-N N#CC1=CC=C(CN(CCC2=NN3C4=NC=CC=C4)CC2=C3O)C=C1 Chemical compound N#CC1=CC=C(CN(CCC2=NN3C4=NC=CC=C4)CC2=C3O)C=C1 RJZWKQKWPZFGGD-UHFFFAOYSA-N 0.000 claims description 3
- YCPIHXNUBRZCML-UHFFFAOYSA-N N1(C(=C2C(=N1)CCN(C2)CC1=CC(F)=CC(F)=C1)O)C1=NC=CC=C1 Chemical compound N1(C(=C2C(=N1)CCN(C2)CC1=CC(F)=CC(F)=C1)O)C1=NC=CC=C1 YCPIHXNUBRZCML-UHFFFAOYSA-N 0.000 claims description 3
- LJVPYHWAWBSMKD-UHFFFAOYSA-N N1(C(=C2C(=N1)CCN(C2)CC1=CC(N(C)C)=CC=C1)O)C1=NC=CC=C1 Chemical compound N1(C(=C2C(=N1)CCN(C2)CC1=CC(N(C)C)=CC=C1)O)C1=NC=CC=C1 LJVPYHWAWBSMKD-UHFFFAOYSA-N 0.000 claims description 3
- UCWUEMMIGBAUAX-UHFFFAOYSA-N N1(C(=C2C(=N1)CCN(C2)CC1=CC2=CC=CC=C2C=N1)O)C1=NC=CC=C1 Chemical compound N1(C(=C2C(=N1)CCN(C2)CC1=CC2=CC=CC=C2C=N1)O)C1=NC=CC=C1 UCWUEMMIGBAUAX-UHFFFAOYSA-N 0.000 claims description 3
- ZRAXAUOGSXEPEI-UHFFFAOYSA-N N1(C(=C2C(=N1)CCN(C2)CC1=CC=C(N(C)C)C=C1)O)C1=NC=CC=C1 Chemical compound N1(C(=C2C(=N1)CCN(C2)CC1=CC=C(N(C)C)C=C1)O)C1=NC=CC=C1 ZRAXAUOGSXEPEI-UHFFFAOYSA-N 0.000 claims description 3
- FIWGUHVRSMJOJY-UHFFFAOYSA-N N1=C(C=CC=C1N1C(=C2C(=N1)CCN(CC1=CC=CC=C1)C2)O)C Chemical compound N1=C(C=CC=C1N1C(=C2C(=N1)CCN(CC1=CC=CC=C1)C2)O)C FIWGUHVRSMJOJY-UHFFFAOYSA-N 0.000 claims description 3
- UTYWOPVQTYSNFV-UHFFFAOYSA-N N1=C2C(=C(N1C1=CC=C(C#N)C=N1)O)CCN(C2)CC1=CC=CC=C1 Chemical compound N1=C2C(=C(N1C1=CC=C(C#N)C=N1)O)CCN(C2)CC1=CC=CC=C1 UTYWOPVQTYSNFV-UHFFFAOYSA-N 0.000 claims description 3
- GSHKXBPLVJLQCL-UHFFFAOYSA-N N1=C2C(=C(N1C1=CC=C(C(=O)O)C=C1)O)CCN(C2)CC1=CC=CC=C1 Chemical compound N1=C2C(=C(N1C1=CC=C(C(=O)O)C=C1)O)CCN(C2)CC1=CC=CC=C1 GSHKXBPLVJLQCL-UHFFFAOYSA-N 0.000 claims description 3
- SWKOZNZVRQHJIJ-UHFFFAOYSA-N N1=C2C(=C(N1C1=CC=CC=C1)O)CCN(C2)CC1=CC=CC=C1 Chemical compound N1=C2C(=C(N1C1=CC=CC=C1)O)CCN(C2)CC1=CC=CC=C1 SWKOZNZVRQHJIJ-UHFFFAOYSA-N 0.000 claims description 3
- DKTIUSFBKHRBJS-UHFFFAOYSA-N N1=C2C(=C(N1C1=NC(=CC=C1)C(F)(F)F)O)CCN(C2)CC1=CC=CC=C1 Chemical compound N1=C2C(=C(N1C1=NC(=CC=C1)C(F)(F)F)O)CCN(C2)CC1=CC=CC=C1 DKTIUSFBKHRBJS-UHFFFAOYSA-N 0.000 claims description 3
- ZZNDSMDYLFDOHF-UHFFFAOYSA-N N1=C2C(=C(N1C1=NC(C)=CC=C1)O)CCN(C2)CC1=CC=CC=C1 Chemical compound N1=C2C(=C(N1C1=NC(C)=CC=C1)O)CCN(C2)CC1=CC=CC=C1 ZZNDSMDYLFDOHF-UHFFFAOYSA-N 0.000 claims description 3
- VECZRVVSGCXNGS-UHFFFAOYSA-N N1=C2C(=C(N1C1=NC(N)=CC=C1)O)CCN(C2)CC1=CC=CC=C1 Chemical compound N1=C2C(=C(N1C1=NC(N)=CC=C1)O)CCN(C2)CC1=CC=CC=C1 VECZRVVSGCXNGS-UHFFFAOYSA-N 0.000 claims description 3
- XHNSGCCKUGMENE-UHFFFAOYSA-N N1=C2C(=C(N1C1=NC=CC=C1)O)CCN(C2)CC1=CC(N(C)C)=CC=C1 Chemical compound N1=C2C(=C(N1C1=NC=CC=C1)O)CCN(C2)CC1=CC(N(C)C)=CC=C1 XHNSGCCKUGMENE-UHFFFAOYSA-N 0.000 claims description 3
- UTHWJGQPBXPVQZ-UHFFFAOYSA-N N1=C2C(=C(N1C1=NC=CC=C1)O)CCN(C2)CC1=CC2=CC=CC=C2C=N1 Chemical compound N1=C2C(=C(N1C1=NC=CC=C1)O)CCN(C2)CC1=CC2=CC=CC=C2C=N1 UTHWJGQPBXPVQZ-UHFFFAOYSA-N 0.000 claims description 3
- HQDNBVWZJSWHAL-UHFFFAOYSA-N N1=C2C(=C(N1C1=NC=CC=C1)O)CCN(C2)CC1=CC=C(F)C=C1 Chemical compound N1=C2C(=C(N1C1=NC=CC=C1)O)CCN(C2)CC1=CC=C(F)C=C1 HQDNBVWZJSWHAL-UHFFFAOYSA-N 0.000 claims description 3
- KYEUDKNBZZHWIS-UHFFFAOYSA-N N1=C2C(=C(N1C1=NC=CC=C1)O)CCN(C2)CC1=CC=C(OC)C=C1 Chemical compound N1=C2C(=C(N1C1=NC=CC=C1)O)CCN(C2)CC1=CC=C(OC)C=C1 KYEUDKNBZZHWIS-UHFFFAOYSA-N 0.000 claims description 3
- PNVDJFDXDYLPEF-UHFFFAOYSA-N N1=C2C(=C(N1C1=NC=CC=C1)O)CCN(C2)CC1=CC=C2N=CC=CC2=C1 Chemical compound N1=C2C(=C(N1C1=NC=CC=C1)O)CCN(C2)CC1=CC=C2N=CC=CC2=C1 PNVDJFDXDYLPEF-UHFFFAOYSA-N 0.000 claims description 3
- TWSJCSWCQXPBGX-UHFFFAOYSA-N N1=C2C(=C(N1C1=NC=CC=C1)O)CCN(C2)CC1=CC=CC=N1 Chemical compound N1=C2C(=C(N1C1=NC=CC=C1)O)CCN(C2)CC1=CC=CC=N1 TWSJCSWCQXPBGX-UHFFFAOYSA-N 0.000 claims description 3
- VRBUBUCLUTZBDA-UHFFFAOYSA-N N1=C2C(=C(N1C1=NC=CC=C1)O)CCN(C2)CC1=CC=NC=C1 Chemical compound N1=C2C(=C(N1C1=NC=CC=C1)O)CCN(C2)CC1=CC=NC=C1 VRBUBUCLUTZBDA-UHFFFAOYSA-N 0.000 claims description 3
- KZHVDHKIPFZRBF-UHFFFAOYSA-N OC1=C(CC(C(C(C=C2)=CC=C2Cl)=O)NC2)C2=NN1C1=NC=CC=C1 Chemical compound OC1=C(CC(C(C(C=C2)=CC=C2Cl)=O)NC2)C2=NN1C1=NC=CC=C1 KZHVDHKIPFZRBF-UHFFFAOYSA-N 0.000 claims description 3
- QLUQLKVYCKEHBA-UHFFFAOYSA-N OC1=C(CCN(CC2=CC=CC=C2)C2)C2=NN1C(C=C1)=CC=C1Br Chemical compound OC1=C(CCN(CC2=CC=CC=C2)C2)C2=NN1C(C=C1)=CC=C1Br QLUQLKVYCKEHBA-UHFFFAOYSA-N 0.000 claims description 3
- CEMGFTMLGMUCNG-UHFFFAOYSA-N OC1=C(CCN(CC2=CC=CC=C2)C2)C2=NN1C(C=CC=C1)=C1Cl Chemical compound OC1=C(CCN(CC2=CC=CC=C2)C2)C2=NN1C(C=CC=C1)=C1Cl CEMGFTMLGMUCNG-UHFFFAOYSA-N 0.000 claims description 3
- UNCXUJXYTSSYPY-UHFFFAOYSA-N OC1=C(CN(CC2=CC3=CC=CC=C3C=C2)CC2)C2=NN1C1=NC=C(C(F)(F)F)C=C1 Chemical compound OC1=C(CN(CC2=CC3=CC=CC=C3C=C2)CC2)C2=NN1C1=NC=C(C(F)(F)F)C=C1 UNCXUJXYTSSYPY-UHFFFAOYSA-N 0.000 claims description 3
- CYTGRHCOHANECI-UHFFFAOYSA-N OC1=C(CN(CC2=CC=CC=C2)CC2)C2=NN1C(C=C1)=CC=C1Br Chemical compound OC1=C(CN(CC2=CC=CC=C2)CC2)C2=NN1C(C=C1)=CC=C1Br CYTGRHCOHANECI-UHFFFAOYSA-N 0.000 claims description 3
- BWQPBOFMVDGAFM-UHFFFAOYSA-N OC1=C(CN(CC2=CC=CC=C2)CC2)C2=NN1C(C=C1)=NC=C1Cl Chemical compound OC1=C(CN(CC2=CC=CC=C2)CC2)C2=NN1C(C=C1)=NC=C1Cl BWQPBOFMVDGAFM-UHFFFAOYSA-N 0.000 claims description 3
- MJATUWURGNCJHP-UHFFFAOYSA-N OC1=C(CN(CC2=CC=CC=C2)CC2)C2=NN1C(C=CC=C1)=C1Cl Chemical compound OC1=C(CN(CC2=CC=CC=C2)CC2)C2=NN1C(C=CC=C1)=C1Cl MJATUWURGNCJHP-UHFFFAOYSA-N 0.000 claims description 3
- JJRJKZDJSNLLLY-UHFFFAOYSA-N OC=1N(N=C2C=1CN(CC2)CC1=CC2=CC=CC=C2C=N1)C1=NC=C(C(F)(F)F)C=C1 Chemical compound OC=1N(N=C2C=1CN(CC2)CC1=CC2=CC=CC=C2C=N1)C1=NC=C(C(F)(F)F)C=C1 JJRJKZDJSNLLLY-UHFFFAOYSA-N 0.000 claims description 3
- 240000007594 Oryza sativa Species 0.000 claims description 3
- 235000007164 Oryza sativa Nutrition 0.000 claims description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 3
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 3
- 235000010323 ascorbic acid Nutrition 0.000 claims description 3
- 239000011668 ascorbic acid Substances 0.000 claims description 3
- 229960005070 ascorbic acid Drugs 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 3
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 3
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims description 3
- 239000001530 fumaric acid Substances 0.000 claims description 3
- 208000037906 ischaemic injury Diseases 0.000 claims description 3
- 230000000302 ischemic effect Effects 0.000 claims description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 3
- 239000011976 maleic acid Substances 0.000 claims description 3
- 235000009566 rice Nutrition 0.000 claims description 3
- 230000009529 traumatic brain injury Effects 0.000 claims description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 claims description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims description 2
- 239000005711 Benzoic acid Substances 0.000 claims description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims description 2
- 235000010233 benzoic acid Nutrition 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 2
- 229910017604 nitric acid Inorganic materials 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 2
- 239000000375 suspending agent Substances 0.000 claims description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 claims 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 claims 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 claims 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 claims 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 claims 1
- 235000021314 Palmitic acid Nutrition 0.000 claims 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 claims 1
- 229930016911 cinnamic acid Natural products 0.000 claims 1
- 235000013985 cinnamic acid Nutrition 0.000 claims 1
- 229960002510 mandelic acid Drugs 0.000 claims 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 claims 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 229940107700 pyruvic acid Drugs 0.000 claims 1
- 229960004889 salicylic acid Drugs 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 7
- 230000015572 biosynthetic process Effects 0.000 description 123
- 238000003786 synthesis reaction Methods 0.000 description 122
- 210000004027 cell Anatomy 0.000 description 53
- 239000003642 reactive oxygen metabolite Substances 0.000 description 47
- 230000004761 fibrosis Effects 0.000 description 44
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 42
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 34
- 238000005160 1H NMR spectroscopy Methods 0.000 description 32
- 230000014509 gene expression Effects 0.000 description 31
- 210000002950 fibroblast Anatomy 0.000 description 27
- 210000001519 tissue Anatomy 0.000 description 27
- 108010006654 Bleomycin Proteins 0.000 description 22
- 229960001561 bleomycin Drugs 0.000 description 22
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 22
- 239000000203 mixture Substances 0.000 description 22
- 238000002360 preparation method Methods 0.000 description 18
- LFULEKSKNZEWOE-UHFFFAOYSA-N propanil Chemical compound CCC(=O)NC1=CC=C(Cl)C(Cl)=C1 LFULEKSKNZEWOE-UHFFFAOYSA-N 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 230000002401 inhibitory effect Effects 0.000 description 17
- 238000004519 manufacturing process Methods 0.000 description 16
- 230000002829 reductive effect Effects 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 15
- 229920001577 copolymer Polymers 0.000 description 15
- 208000002260 Keloid Diseases 0.000 description 14
- 210000001117 keloid Anatomy 0.000 description 14
- 206010023330 Keloid scar Diseases 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 208000024827 Alzheimer disease Diseases 0.000 description 10
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 description 10
- 210000004072 lung Anatomy 0.000 description 10
- 230000004770 neurodegeneration Effects 0.000 description 10
- 239000013641 positive control Substances 0.000 description 10
- 230000002265 prevention Effects 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 229920002678 cellulose Polymers 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 208000019423 liver disease Diseases 0.000 description 9
- 208000015122 neurodegenerative disease Diseases 0.000 description 9
- 238000005481 NMR spectroscopy Methods 0.000 description 8
- 235000010980 cellulose Nutrition 0.000 description 8
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 8
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 7
- 108010022452 Collagen Type I Proteins 0.000 description 7
- 102000015225 Connective Tissue Growth Factor Human genes 0.000 description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000003176 fibrotic effect Effects 0.000 description 7
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 7
- 125000003367 polycyclic group Chemical group 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 239000001913 cellulose Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 125000005843 halogen group Chemical group 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 description 6
- 229960004378 nintedanib Drugs 0.000 description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
- 238000001308 synthesis method Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- FMGYKKMPNATWHP-UHFFFAOYSA-N Cyperquat Chemical compound C1=C[N+](C)=CC=C1C1=CC=CC=C1 FMGYKKMPNATWHP-UHFFFAOYSA-N 0.000 description 5
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 5
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 5
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 208000017442 Retinal disease Diseases 0.000 description 5
- 125000003342 alkenyl group Chemical group 0.000 description 5
- 125000000304 alkynyl group Chemical group 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 238000012790 confirmation Methods 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- 210000002744 extracellular matrix Anatomy 0.000 description 5
- 208000006454 hepatitis Diseases 0.000 description 5
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000007845 reactive nitrogen species Substances 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 229920002554 vinyl polymer Polymers 0.000 description 5
- 208000019901 Anxiety disease Diseases 0.000 description 4
- 102000012422 Collagen Type I Human genes 0.000 description 4
- 206010067889 Dementia with Lewy bodies Diseases 0.000 description 4
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 4
- 206010012689 Diabetic retinopathy Diseases 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 208000009829 Lewy Body Disease Diseases 0.000 description 4
- 201000002832 Lewy body dementia Diseases 0.000 description 4
- KNDIBHLKRVJTHA-UHFFFAOYSA-N N1=C2C(=C(N1C1=NC=CC=C1)O)CCNC2 Chemical compound N1=C2C(=C(N1C1=NC=CC=C1)O)CCNC2 KNDIBHLKRVJTHA-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 208000028017 Psychotic disease Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 235000010443 alginic acid Nutrition 0.000 description 4
- 229920000615 alginic acid Polymers 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000036506 anxiety Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 208000033679 diabetic kidney disease Diseases 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 229960003638 dopamine Drugs 0.000 description 4
- UQOMEAWPKSISII-UHFFFAOYSA-N ethyl 1-benzyl-3-oxopiperidine-4-carboxylate;hydron;chloride Chemical compound Cl.C1C(=O)C(C(=O)OCC)CCN1CC1=CC=CC=C1 UQOMEAWPKSISII-UHFFFAOYSA-N 0.000 description 4
- YPFMNHZRNXPYBG-UHFFFAOYSA-N ethyl 1-benzyl-4-oxopiperidin-1-ium-3-carboxylate;chloride Chemical compound Cl.C1CC(=O)C(C(=O)OCC)CN1CC1=CC=CC=C1 YPFMNHZRNXPYBG-UHFFFAOYSA-N 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 231100000283 hepatitis Toxicity 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 210000000651 myofibroblast Anatomy 0.000 description 4
- 210000000440 neutrophil Anatomy 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 208000017520 skin disease Diseases 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 229920003176 water-insoluble polymer Polymers 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 230000003542 behavioural effect Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 229920002301 cellulose acetate Polymers 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 125000002541 furyl group Chemical group 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 210000004024 hepatic stellate cell Anatomy 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 3
- 150000002460 imidazoles Chemical class 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 210000004558 lewy body Anatomy 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 210000005228 liver tissue Anatomy 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 230000016273 neuron death Effects 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000004792 oxidative damage Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229920000193 polymethacrylate Polymers 0.000 description 3
- NWELCUKYUCBVKK-UHFFFAOYSA-N pyridin-2-ylhydrazine Chemical class NNC1=CC=CC=N1 NWELCUKYUCBVKK-UHFFFAOYSA-N 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- RGGOWBBBHWTTRE-UHFFFAOYSA-N (4-bromophenyl)hydrazine;hydron;chloride Chemical compound Cl.NNC1=CC=C(Br)C=C1 RGGOWBBBHWTTRE-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 2
- 102100026882 Alpha-synuclein Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 208000019505 Deglutition disease Diseases 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- 208000032859 Synucleinopathies Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- 108090000185 alpha-Synuclein Proteins 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 210000003123 bronchiole Anatomy 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 229940096422 collagen type i Drugs 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 210000005064 dopaminergic neuron Anatomy 0.000 description 2
- 230000003291 dopaminomimetic effect Effects 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 235000011087 fumaric acid Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 2
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 2
- 229940046813 glyceryl palmitostearate Drugs 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 229960002900 methylcellulose Drugs 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 229910052901 montmorillonite Inorganic materials 0.000 description 2
- 206010028537 myelofibrosis Diseases 0.000 description 2
- 210000003061 neural cell Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- JOVOSQBPPZZESK-UHFFFAOYSA-N phenylhydrazine hydrochloride Chemical compound Cl.NNC1=CC=CC=C1 JOVOSQBPPZZESK-UHFFFAOYSA-N 0.000 description 2
- 229940038531 phenylhydrazine hydrochloride Drugs 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 229940083542 sodium Drugs 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 238000007039 two-step reaction Methods 0.000 description 2
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- UXJYFOOFLZGBEK-UHFFFAOYSA-N (5-chloropyridin-2-yl)hydrazine Chemical compound NNC1=CC=C(Cl)C=N1 UXJYFOOFLZGBEK-UHFFFAOYSA-N 0.000 description 1
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 1
- DTCCVIYSGXONHU-CJHDCQNGSA-N (z)-2-(2-phenylethenyl)but-2-enedioic acid Chemical compound OC(=O)\C=C(C(O)=O)\C=CC1=CC=CC=C1 DTCCVIYSGXONHU-CJHDCQNGSA-N 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 description 1
- HFFXLYHRNRKAPM-UHFFFAOYSA-N 2,4,5-trichloro-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C(=CC(Cl)=C(Cl)C=2)Cl)=N1 HFFXLYHRNRKAPM-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- ADODRSVGNHNKAT-UHFFFAOYSA-N 2-Chlorophenylhydrazine hydrochloride Chemical compound Cl.NNC1=CC=CC=C1Cl ADODRSVGNHNKAT-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- FZIPCQLKPTZZIM-UHFFFAOYSA-N 2-oxidanylpropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O FZIPCQLKPTZZIM-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- PYSRRFNXTXNWCD-UHFFFAOYSA-N 3-(2-phenylethenyl)furan-2,5-dione Chemical compound O=C1OC(=O)C(C=CC=2C=CC=CC=2)=C1 PYSRRFNXTXNWCD-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 description 1
- MGWGWNFMUOTEHG-UHFFFAOYSA-N 4-(3,5-dimethylphenyl)-1,3-thiazol-2-amine Chemical compound CC1=CC(C)=CC(C=2N=C(N)SC=2)=C1 MGWGWNFMUOTEHG-UHFFFAOYSA-N 0.000 description 1
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical class OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- PCNFLKVWBDNNOW-UHFFFAOYSA-N 4-hydrazinylbenzoic acid Chemical compound NNC1=CC=C(C(O)=O)C=C1 PCNFLKVWBDNNOW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 229920000945 Amylopectin Chemical class 0.000 description 1
- 229920000856 Amylose Chemical class 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 239000001904 Arabinogalactan Chemical class 0.000 description 1
- 229920000189 Arabinogalactan Chemical class 0.000 description 1
- 206010054793 Arterial fibrosis Diseases 0.000 description 1
- 206010058029 Arthrofibrosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 1
- 0 CCOC(C(C*(*)CC1)C1=O)=O Chemical compound CCOC(C(C*(*)CC1)C1=O)=O 0.000 description 1
- 101150008656 COL1A1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010007749 Cataract diabetic Diseases 0.000 description 1
- 208000011545 Cataract-glaucoma syndrome Diseases 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 229920001747 Cellulose diacetate Polymers 0.000 description 1
- DQEFEBPAPFSJLV-UHFFFAOYSA-N Cellulose propionate Chemical compound CCC(=O)OCC1OC(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C1OC1C(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C(COC(=O)CC)O1 DQEFEBPAPFSJLV-UHFFFAOYSA-N 0.000 description 1
- 229920002284 Cellulose triacetate Polymers 0.000 description 1
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010072268 Drug-induced liver injury Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229920000896 Ethulose Polymers 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000001859 Ethyl hydroxyethyl cellulose Substances 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical group CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- 229920003149 Eudragit® E 100 Polymers 0.000 description 1
- 229920003136 Eudragit® L polymer Polymers 0.000 description 1
- 229920003163 Eudragit® NE 30 D Polymers 0.000 description 1
- 229920003151 Eudragit® RL polymer Polymers 0.000 description 1
- 229920003137 Eudragit® S polymer Polymers 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 208000024934 IgG4-related mediastinitis Diseases 0.000 description 1
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000009784 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Human genes 0.000 description 1
- 108010020246 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Proteins 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000002805 Mediastinal fibrosis Diseases 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010048654 Muscle fibrosis Diseases 0.000 description 1
- 208000002033 Myoclonus Diseases 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 125000004633 N-oxo-pyridyl group Chemical group 0.000 description 1
- YLNLHUKTZODWAF-UHFFFAOYSA-N N1=C2C(=C(N1C1=NC=CC=C1)O)CCN(C2)CC#C Chemical compound N1=C2C(=C(N1C1=NC=CC=C1)O)CCN(C2)CC#C YLNLHUKTZODWAF-UHFFFAOYSA-N 0.000 description 1
- DONRUDLIBRMVGC-UHFFFAOYSA-N N1=C2C(=C(N1C1=NC=CC=C1)O)CCN(C2)CC1=CC(C(F)(F)F)=CC=C1 Chemical compound N1=C2C(=C(N1C1=NC=CC=C1)O)CCN(C2)CC1=CC(C(F)(F)F)=CC=C1 DONRUDLIBRMVGC-UHFFFAOYSA-N 0.000 description 1
- 208000003510 Nephrogenic Fibrosing Dermopathy Diseases 0.000 description 1
- 206010067467 Nephrogenic systemic fibrosis Diseases 0.000 description 1
- 208000009905 Neurofibromatoses Diseases 0.000 description 1
- PYIAFJVCALXWRT-UHFFFAOYSA-N OC(C(C=C1)=CC=C1N1N=C(CN(CC2=CC=CC=C2)CC2)C2=C1O)=O.Cl Chemical compound OC(C(C=C1)=CC=C1N1N=C(CN(CC2=CC=CC=C2)CC2)C2=C1O)=O.Cl PYIAFJVCALXWRT-UHFFFAOYSA-N 0.000 description 1
- OHBZKFKIZNCYJF-UHFFFAOYSA-N OC1=C(CCN(CC2=CC=CC=C2)C2)C2=NN1C(C=C1)=CC=C1Br.Cl Chemical compound OC1=C(CCN(CC2=CC=CC=C2)C2)C2=NN1C(C=C1)=CC=C1Br.Cl OHBZKFKIZNCYJF-UHFFFAOYSA-N 0.000 description 1
- PKLCDNSSQZTVRZ-UHFFFAOYSA-N OC1=C(CCN(CC2=CC=CC=C2)C2)C2=NN1C1=CC=CC=C1.Cl Chemical compound OC1=C(CCN(CC2=CC=CC=C2)C2)C2=NN1C1=CC=CC=C1.Cl PKLCDNSSQZTVRZ-UHFFFAOYSA-N 0.000 description 1
- DTFDJOKBXSFSCE-UHFFFAOYSA-N OC1=C(CN(CC2=CC=CC=C2)CC2)C2=NN1C(C=C1)=CC=C1Br.Cl Chemical compound OC1=C(CN(CC2=CC=CC=C2)CC2)C2=NN1C(C=C1)=CC=C1Br.Cl DTFDJOKBXSFSCE-UHFFFAOYSA-N 0.000 description 1
- WAJHYWNTGGTGAX-UHFFFAOYSA-N OC1=C(CN(CC2=CC=CC=C2)CC2)C2=NN1C(C=CC=C1)=C1Cl.Cl Chemical compound OC1=C(CN(CC2=CC=CC=C2)CC2)C2=NN1C(C=CC=C1)=C1Cl.Cl WAJHYWNTGGTGAX-UHFFFAOYSA-N 0.000 description 1
- ZHOSFHQSPVSRTJ-UHFFFAOYSA-N OC1=C(CN(CC2=CC=CC=C2)CC2)C2=NN1C1=CC=CC=C1.Cl Chemical compound OC1=C(CN(CC2=CC=CC=C2)CC2)C2=NN1C1=CC=CC=C1.Cl ZHOSFHQSPVSRTJ-UHFFFAOYSA-N 0.000 description 1
- BPMGIWKUCGURKN-UHFFFAOYSA-N Oc1c(CCN(Cc2ccccc2)C2)c2n[n]1-c1ccccc1C1CC1 Chemical compound Oc1c(CCN(Cc2ccccc2)C2)c2n[n]1-c1ccccc1C1CC1 BPMGIWKUCGURKN-UHFFFAOYSA-N 0.000 description 1
- HLCABKQLOLAFKQ-UHFFFAOYSA-N Oc1c(CN(Cc2ccccc2)CC2)c2n[n]1-c1ccc(C(F)(F)F)cn1 Chemical compound Oc1c(CN(Cc2ccccc2)CC2)c2n[n]1-c1ccc(C(F)(F)F)cn1 HLCABKQLOLAFKQ-UHFFFAOYSA-N 0.000 description 1
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010051657 Ovarian fibrosis Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 208000002192 Parkinson disease 3 Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 206010038748 Restrictive cardiomyopathy Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 101150110423 SNCA gene Proteins 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010050207 Skin fibrosis Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229920000147 Styrene maleic anhydride Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010067269 Uterine fibrosis Diseases 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 1
- PDRJYGJBOYHPJC-UHFFFAOYSA-N [5-(trifluoromethyl)pyridin-2-yl]hydrazine Chemical compound NNC1=CC=C(C(F)(F)F)C=N1 PDRJYGJBOYHPJC-UHFFFAOYSA-N 0.000 description 1
- UGXQOOQUZRUVSS-ZZXKWVIFSA-N [5-[3,5-dihydroxy-2-(1,3,4-trihydroxy-5-oxopentan-2-yl)oxyoxan-4-yl]oxy-3,4-dihydroxyoxolan-2-yl]methyl (e)-3-(4-hydroxyphenyl)prop-2-enoate Chemical class OC1C(OC(CO)C(O)C(O)C=O)OCC(O)C1OC1C(O)C(O)C(COC(=O)\C=C\C=2C=CC(O)=CC=2)O1 UGXQOOQUZRUVSS-ZZXKWVIFSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- UTKBLLDLHPDWDU-ODZAUARKSA-N acetic acid;(z)-but-2-enedioic acid Chemical compound CC(O)=O.OC(=O)\C=C/C(O)=O UTKBLLDLHPDWDU-ODZAUARKSA-N 0.000 description 1
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 1
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000002535 acidifier Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 235000019312 arabinogalactan Nutrition 0.000 description 1
- 229920000617 arabinoxylan Polymers 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 208000031326 autosomal dominant parkinson disease 3 Diseases 0.000 description 1
- 239000002610 basifying agent Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 208000013404 behavioral symptom Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- VAXVWHDAGLTVRV-UHFFFAOYSA-N benzoic acid;phthalic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1C(O)=O VAXVWHDAGLTVRV-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- VHEMBTYWURNBQQ-UHFFFAOYSA-N butanoic acid;phthalic acid Chemical compound CCCC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O VHEMBTYWURNBQQ-UHFFFAOYSA-N 0.000 description 1
- NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 230000009787 cardiac fibrosis Effects 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 229920006218 cellulose propionate Polymers 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- AOGYCOYQMAVAFD-UHFFFAOYSA-N chlorocarbonic acid Chemical compound OC(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-N 0.000 description 1
- 230000001587 cholestatic effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001531 copovidone Polymers 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000002188 cycloheptatrienyl group Chemical group C1(=CC=CC=CC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 201000007025 diabetic cataract Diseases 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 231100000594 drug induced liver disease Toxicity 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 230000002888 effect on disease Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 201000010048 endomyocardial fibrosis Diseases 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- XEPZKCVKBIJDII-UHFFFAOYSA-N ethyl 1-benzyl-3-hydroxypiperidine-4-carboxylate Chemical compound C1C(O)C(C(=O)OCC)CCN1CC1=CC=CC=C1 XEPZKCVKBIJDII-UHFFFAOYSA-N 0.000 description 1
- JYFGIESQUYQLGM-UHFFFAOYSA-N ethyl 1-benzyl-3-oxopiperidine-4-carboxylate Chemical compound C1C(=O)C(C(=O)OCC)CCN1CC1=CC=CC=C1 JYFGIESQUYQLGM-UHFFFAOYSA-N 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019326 ethyl hydroxyethyl cellulose Nutrition 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- QFWPJPIVLCBXFJ-UHFFFAOYSA-N glymidine Chemical compound N1=CC(OCCOC)=CN=C1NS(=O)(=O)C1=CC=CC=C1 QFWPJPIVLCBXFJ-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000001341 hydroxy propyl starch Chemical class 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 108700016226 indium-bleomycin Proteins 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- IQSHMXAZFHORGY-UHFFFAOYSA-N methyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound COC(=O)C=C.CC(=C)C(O)=O IQSHMXAZFHORGY-UHFFFAOYSA-N 0.000 description 1
- MYSWGNHLJGOCPT-UHFFFAOYSA-N methyl prop-2-enoate;prop-2-enoic acid Chemical compound OC(=O)C=C.COC(=O)C=C MYSWGNHLJGOCPT-UHFFFAOYSA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- GRFNBEZIAWKNCO-UHFFFAOYSA-N mhp Natural products OC1=CC=CN=C1 GRFNBEZIAWKNCO-UHFFFAOYSA-N 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000002071 myeloproliferative effect Effects 0.000 description 1
- DNKKLDKIFMDAPT-UHFFFAOYSA-N n,n-dimethylmethanamine;2-methylprop-2-enoic acid Chemical compound CN(C)C.CC(=C)C(O)=O.CC(=C)C(O)=O DNKKLDKIFMDAPT-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 201000003142 neovascular glaucoma Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 201000004931 neurofibromatosis Diseases 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- KSZMOTXUZYNGAZ-UHFFFAOYSA-N nitrosoperoxycarbonic acid Chemical compound OC(=O)OON=O KSZMOTXUZYNGAZ-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 150000002927 oxygen compounds Chemical class 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 206010035653 pneumoconiosis Diseases 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001483 poly(ethyl methacrylate) polymer Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000001725 pyrenyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- AQIDWPCFDNAMQW-UHFFFAOYSA-N pyridin-3-ol Chemical compound OC1=C=NC=C[CH]1 AQIDWPCFDNAMQW-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000002793 renal fibrosis Diseases 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 239000000790 retinal pigment Substances 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 102200036626 rs104893877 Human genes 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 208000011571 secondary malignant neoplasm Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000013424 sirius red staining Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960005187 telmisartan Drugs 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- JADVWWSKYZXRGX-UHFFFAOYSA-M thioflavine T Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C1=[N+](C)C2=CC=C(C)C=C2S1 JADVWWSKYZXRGX-UHFFFAOYSA-M 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- AYNNSCRYTDRFCP-UHFFFAOYSA-N triazene Chemical compound NN=N AYNNSCRYTDRFCP-UHFFFAOYSA-N 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- PKIDNTKRVKSLDB-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;hydrate Chemical compound O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PKIDNTKRVKSLDB-UHFFFAOYSA-K 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Definitions
- the present invention relates to a novel pyrazole derivative having excellent oxidative stress inhibitory activity, a method for preparing the same, and a pharmaceutical composition thereof.
- Oxidative stress refers to a phenomenon in which the production of reactive oxygen species or reactive nitrogen species and the antioxidant defense mechanism are out of balance in biomolecules, cells, and tissues in vivo, and the production of reactive oxygen species or reactive nitrogen species becomes relatively excessive. In this case, tissue damage is usually caused.
- Reactive oxygen species are oxygen free radicals produced due to the chemical properties of oxygen and oxygen compounds derived therefrom.
- Cancer Associated Fibroblast plays an important role. It is known that cancer-associated fibroblasts are activated by ROS to promote tumor immune evasion and act on cancer malignancy and metastasis. Therefore, recently, cancer-related fibroblasts are emerging as a new target for cancer treatment.
- ROS reactive oxygen species
- the brain is a highly metabolized tissue and therefore very vulnerable to oxidative damage. Therefore, many studies have been conducted to effectively remove ROS for the treatment of various neurodegenerative diseases (Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, Alzheimer's disease, multiple sclerosis, ischemic and traumatic brain injury, etc.), but without success. Recently, as ROS was found to be an important factor in these brain diseases, the possibility of treatment through ROS inhibition was reported.
- Keloid is a type of benign tumor disease in which the connective tissue of the skin proliferates pathologically, making hard bumps, and the epidermis becomes thin and shiny and reddish. It has been reported that the onset and exacerbation of keloids is also one of the reasons for the overexpression of connective tissue growth factor (CTGF) by ROS generated by TGF- ⁇ 1 stimulation.
- CGF connective tissue growth factor
- ROS plays an important role. I.e. high blood sugar is caused to generate an increase in ROS, at which time generated ROS can lead to such diabetic nephropathy (diabetic nephropathy), and diabetic retinopathy (diabetic retinopathy) through a series of steps leading to apoptosis of kidney cells and retinal cells .
- the present inventors can develop a therapeutic agent for cancer, inflammatory disease, fibrotic disease, neurodegenerative disease, liver disease, skin disease, or retinal disease caused by oxidative stress by using a molecular mechanism that inhibits the generation of oxidative stress.
- the present invention was completed by confirming that the novel pyrazole derivative of the present invention has excellent ROS generation inhibitory activity and can be used for the treatment of various diseases related to oxidative stress.
- Patent Document 1 WO 2016-207785
- Patent Document 2 WO 2015-144801
- Non-Patent Document 1 Mengjia Song, Xinfeng Chen, et al. Chinese Journal of Cancer Research, 2018, 30(2):157-172.
- Non-Patent Document 2 Lan T, Kisseleva T, Brenner DA. PLoS One 2015;10:e0129743.
- Non-Patent Document 3 Merry W. Ma, Jin Wang, et al. Molecular neurodegeneration, 12:7, 2017.
- Non-Patent Document 4 Alessandro G. Fois. Panagiotis Paligiannis et al. Respir Res. 2018, 19:51.
- Non-Patent Document 5 Rohan Samarakoon, Jessica M. Overstreet et al. Cell Signal, 2013. Jan, 25(1), 264-268.
- An object of the present invention is to provide a novel pyrazole derivative, a compound of formula (I), a solvate, a stereoisomer or a pharmaceutically acceptable salt thereof.
- An object of the present invention is to provide a pharmaceutical composition
- a pharmaceutical composition comprising a compound of formula (I), a solvate, a stereoisomer or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
- An object of the present invention is to provide a method for treating a disease associated with oxidative stress by administering to a subject a compound of formula (I), a solvate, a stereoisomer, or a pharmaceutically acceptable salt thereof.
- the present invention aims to provide a process for the preparation of compounds of formula (I).
- An object of the present invention is to provide a use of a compound of formula (I), a solvate, a stereoisomer or a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical composition for the prevention or treatment of a disease associated with oxidative stress.
- the present invention provides a novel pyrazole derivative, a compound represented by the following formula (I), a solvate, a stereoisomer, or a pharmaceutically acceptable salt thereof.
- X, Y are CR1R2 or NR3;
- R1, R2 or R3 are the same as or different from each other and are each independently selected from Ra-L-, Ra-LCO-, Ra-L-NHCO-, Ra-L-OCO-, Ra-L-SO 2 -;
- Ra is hydrogen, deuterium, cyan, halogen, nitro, haloalkyl, substituted or unsubstituted C1-C10 straight chain or branched alkyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted C5-C20 aryl, or substituted or unsubstituted C5-C20 heteroaryl, said heteroaryl containing 1, 2 or 3 heteroatoms of O, N, S;
- L is selected from a direct bond, C1-C5 alkylene, substituted or unsubstituted C5-C10 arylene;
- R4 is selected from hydrogen or substituted or unsubstituted C1-C10 alkyl
- A is CR5 or N
- B is CR6 or N
- D is CR7 or N
- E is CR8 or N
- G is CR9 or N;
- R5 to R9 are the same or different, and each independently hydrogen, deuterium, cyan, halogen, haloalkyl, carbonyl, nitro, carboxyl, C1-C5 alkoxy, substituted or unsubstituted C1-C10 straight-chain or branched alkyl , substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted amine, substituted or unsubstituted C5-C20 aryl, or substituted or unsubstituted C5-C20 heteroaryl, and two or more adjacent groups are may be combined with each other to form a substituted or unsubstituted aromatic hydrocarbon ring, wherein the aromatic hydrocarbon ring is a C5-C10 heteroaryl ring containing 0, 1, 2 or 3 heteroatoms selected from N, O, S, or can form an aryl ring;
- substituted C1-C10 straight-chain or branched alkyl may optionally be partially unsaturated and is independently deuterium, halogen, cyan, nitro, carboxyl, substituted or unsubstituted amine, substituted or unsubstituted C5-C20 aryl or C5 which may be substituted with one or more substituents selected from -C20 heteroaryl, substituted or unsubstituted C3-C8 cycloalkyl;
- said substituted C3-C8 cycloalkyl is independently deuterium, halogen, cyan, nitro, carboxyl, substituted or unsubstituted amine, substituted or unsubstituted C5-C20 aryl or C5-C20 heteroaryl, C1-C5 alkoxy;
- One or more substituents selected from C1-C5 haloalkyl or two or more substituents that are the same or different from each other may be linked and substituted;
- substituted C5-C20 aryl or substituted C5-C20 heteroaryl is independently deuterium, halogen, cyan, nitro, carboxyl, substituted or unsubstituted amine, C1-C5 alkoxy, C1-C5 haloalkyl, C1-C10 one or more substituents selected from alkyl, C3-C8 cycloalkyl, C1-C10 alkyl, C5-C20 aryl, C1-C10 alkyl, or two or more identical or different substituents may be linked and substituted;
- the substituted amine may be substituted with one or two C1-C5 alkyl groups
- the substituted C5-C10 arylene may be substituted by one or more substituents selected from C1-C3 alkyl, halogen, cyan, amine, nitro, and deuterium, or two or more substituents that are the same or different from each other.
- the present invention provides a compound, solvate, stereoisomer, or pharmaceutically acceptable salt thereof represented by the above formula (I) for use in the treatment of diseases related to oxidative stress.
- the present invention provides a pharmaceutical composition for treating a disease related to oxidative stress, comprising the compound, solvate, stereoisomer, or pharmaceutically acceptable salt thereof represented by the above formula (I) as an active ingredient and an acceptable carrier. do.
- the present invention provides a method for treating a disease related to oxidative stress, comprising administering to a subject in need of treatment an effective amount of a compound, solvate, stereoisomer, or pharmaceutically acceptable salt thereof represented by the formula (I) do.
- the present invention also provides the use of a compound of formula (I), a solvate, a stereoisomer or a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical composition for the prevention or treatment of a disease associated with oxidative stress.
- novel pyrazole derivative of the present invention and a pharmaceutical composition comprising the same provide excellent effects on diseases related to oxidative stress.
- novel pyrazole derivative effectively inhibited oxidative stress and the production of ⁇ SMA, extracellular matrix, or IL-1 ⁇ in various cells, particularly cancer, inflammatory diseases, fibrotic diseases, neurodegenerative diseases, liver due to oxidative stress. It has the effect of effectively improving diseases, skin diseases or retinal diseases.
- Figure 2 shows the effect of the compounds of the synthesis example inhibiting the expression of ⁇ SMA induced by TGF- ⁇ 1 in ARPE19 cells.
- 3a and 3b show the effect of the compound of Synthesis Example 3 to inhibit the expression of ⁇ SMA induced by TGF- ⁇ 1 in various cells.
- FIG. 6 shows the effect of inhibiting the expression of ⁇ SMA by the compound of Synthesis Example in the lung tissue of the lung fibrosis model.
- straight-chain or branched alkyl refers to a straight-chain, branched monovalent saturated hydrocarbon group. Unless otherwise defined, the alkyl group generally contains 1 to 10, 1 to 8, 1 to 6, 1 to 4, or 1 to 3 carbon atoms. Examples of alkyl groups include methyl, ethyl, propyl (eg n-propyl and isopropyl), butyl (eg n-butyl, isobutyl, and t-butyl), pentyl (eg n-pentyl, isopentyl, and neo).
- propyl eg n-propyl and isopropyl
- butyl eg n-butyl, isobutyl, and t-butyl
- pentyl eg n-pentyl, isopentyl, and neo
- the alkyl group may be alkenyl or alkynyl, optionally partially unsaturated.
- the alkyl group may be further substituted by other substituents.
- alkenyl refers to a monovalent unsaturated hydrocarbon group having one or more straight or branched carbon-carbon double bonds. Unless otherwise defined, the alkenyl group generally contains 2-10, 2-8, 2-6, 2-4, or 2-3 carbon atoms. Alkenyl groups include, for example, ethenyl, n-propenyl, isopropenyl, cyclohexenyl, and the like, and may be further substituted by other substituents.
- alkynyl refers to a monovalent unsaturated hydrocarbon group having at least one carbon-carbon triple bond in a straight or branched form. Unless otherwise defined, the alkynyl group generally contains 2-10, 2-8, 2-6, 2-4, or 2-3 carbon atoms. The alkynyl group includes, for example, ethynyl, n-propynyl, and the like and may be further substituted by other substituents.
- alkoxy may be a straight chain, branched chain or cyclic chain. Although carbon number of an alkoxy group is not specifically limited, It is preferable that it is C1-C5. Specifically, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, sec-butoxy, n-pentyloxy, neopentyloxy, isopentyloxy, etc. may be, but is not limited thereto.
- haloalkyl refers to an alkyl group having one or more halogen substituents.
- Haloalkyl includes -CF 3 , -C 2 F 5 , -CHF 2 , -CCl 3 , -CHCl 2 , and -C 2 Cl 5 .
- the haloalkyl group generally contains 1 to 6, 1 to 5, 1 to 4 or 1 to 3 carbon atoms, and may be further substituted by other substituents.
- cycloalkyl refers to a non-aromatic carbocyclic ring comprising cyclized alkyl, alkenyl and alkynyl groups.
- the cycloalkyl group may include a monocyclic or polycyclic ring. Such polycyclics are, for example, those having 2, 3 or 4 fused rings. Unless otherwise defined, the cycloalkyl group generally contains 3 to 10, or 3 to 7 ring carbon atoms.
- Cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclohexadienyl, cycloheptatrienyl, and the like, and may be further substituted by other substituents.
- aryl refers to an aromatic hydrocarbon group having a monocyclic or polycyclic ring, and may be further substituted by other substituents.
- polycyclic means a group in which an aryl group is directly connected to another ring group or condensed.
- the other ring group may be an aryl group, but may be a different type of ring group, for example, a cycloalkyl group, a heteroaryl group, or the like.
- the polycyclic ring may have, for example, 2, 3 or 4 rings.
- the aryl group generally has 5 to 20, 6 to 15, 6 to 12, or 6 to 10 carbon ring atoms.
- the aryl group includes, for example, phenyl, naphthyl (eg, naphthyl-1-yl and naphthyl-2-yl), biphenyl, anthracenyl, phenanthrenyl, and the like.
- heteroaryl refers to a monovalent aromatic group having at least one hetero atom selected from N, O and S as a ring member.
- the heteroaryl group includes a monocyclic or polycyclic structure.
- the polycyclic ring may have, for example, 2, 3 or 4 condensed rings.
- the heteroaryl group generally contains 3 to 10, 3 to 7, or 3 to 5 ring atoms.
- the heteroaryl group may include 1, 2 or 3 heteroatoms.
- a heteroaryl group is, for example, furanyl, pyridyl, N-oxopyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, furyl, quinolyl, isoquinolyl, thienyl , imidazolyl, furanyl, thiazolyl, indolyl, pyryl, oxazolyl, benzofuryl, benzothienyl, benzthiazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, ind zolyl, 1,2,4-thiadiazolyl, isothiazolyl, benzothienyl, purinyl, benzimidazolyl, indolinyl, and the like, and may be further substituted by other substituents.
- halogen refers to fluoro, chloro, bromo, or iodo.
- arylalkyl refers to an alkyl group substituted by an aryl group.
- Aryl and alkyl are as defined above
- heteroarylalkyl refers to an alkyl group substituted by a heteroaryl group. “Heteroaryl” and “alkyl” are as defined above.
- the "substituted or unsubstituted amine group” may be selected from the group consisting of a monoalkylamine group, -NH2, and a dialkylamine group, and "alkyl” is as defined above.
- Specific examples of the substituted or unsubstituted amine group include NH2, a methylamine group, a dimethylamine group, an ethylamine group, a diethylamine group, and the like, but are not limited thereto.
- arylene group means that the aryl group has two bonding positions, that is, a divalent group. Except that each of these is a divalent group, the description of the aryl group described above may be applied.
- substitution means that a hydrogen atom bonded to a carbon atom of a compound is replaced with another substituent, and the position to be substituted is not limited as long as the position at which the hydrogen atom is substituted, that is, the position where the substituent is substitutable, is not limited,
- two or more substituents may be the same or different from each other, and two or more identical or different substituents may be linked and substituted.
- substituted straight-chain or branched alkyl is a form of C1-C10 straight-chain or branched alkyl substituted with the following substituents on carbon atoms. Specifically, selected from deuterium, halogen, cyan, nitro, carboxyl, substituted or unsubstituted amine, substituted or unsubstituted C5-C20 aryl or C5-C20 heteroaryl, C1-C5 alkoxy, C1-C5 haloalkyl One or more substituents or the same or different two or more substituents are linked and substituted.
- substituents include, but are not limited to, trifluoromethyl, halogen, cyan, methoxy, carboxyl, methyl, amino, nitro dimethylamino, cyclopropyl substituted imidazole, and the like.
- substituted cycloalkyl refers to C3-C8 cycloalkyl with deuterium, halogen, cyan, nitro, carboxyl, substituted or unsubstituted amine, substituted or unsubstituted C5-C20 aryl or C5-C20 heteroaryl , C1-C5 alkoxy, C1-C5 haloalkyl at least one substituent selected from, or the same or different substituents are connected and substituted.
- substituents include, but are not limited to, trifluoromethyl, halogen, cyan, methoxy, carboxyl, methyl, amino, nitro dimethylamino, cyclopropyl substituted imidazole, and the like.
- substituted aryl or “substituted heteroaryl” refers to C5-C20 aryl or C5-C50 heteroaryl with deuterium, halogen, cyan, nitro, carboxyl, substituted or unsubstituted amine, C1-C5 alkoxy , C1-C5 haloalkyl, C1-C10 alkyl, C3-C8 cycloalkyl, C1-C10 alkyl, C5-C20 aryl, C1-C10 alkyl, at least one substituent selected from, or the same or different substituents are linked and substituted am.
- substituents include, but are not limited to, trifluoromethyl, halogen, cyan, methoxy, carboxyl, methyl, amino, nitro dimethylamino, cyclopropyl substituted imidazole, and the like.
- the "adjacent" group refers to a substituent substituted on an atom directly connected to the atom in which the substituent is substituted, a substituent sterically closest to the substituent, or another substituent substituted at the atom in which the substituent is substituted. there is.
- two substituents substituted at an ortho position in a benzene ring and two substituents substituted at the same carbon in an aliphatic ring may be interpreted as "adjacent" to each other.
- the present invention provides a compound, solvate, stereoisomer, or pharmaceutically acceptable salt thereof represented by the following formula (I).
- X, Y are CR1R2 or NR3;
- R1, R2 or R3 are the same as or different from each other and are each independently selected from Ra-L-, Ra-L-CO-, Ra-L-NHCO-, Ra-L-OCO-, Ra-L-SO 2 - become;
- Ra is hydrogen, deuterium, cyan, halogen, nitro, haloalkyl, substituted or unsubstituted C1-C10 straight chain or branched alkyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted C5-C20 aryl, or substituted or unsubstituted C5-C20 heteroaryl, said heteroaryl containing 1, 2 or 3 heteroatoms of O, N, S;
- L is selected from a direct bond, C1-C5 alkylene, substituted or unsubstituted C5-C10 arylene;
- R4 is selected from hydrogen or substituted or unsubstituted C1-C10 alkyl
- A is CR5 or N
- B is CR6 or N
- D is CR7 or N
- E is CR8 or N
- G is CR9 or N;
- R5 to R9 are the same or different, and each independently hydrogen, deuterium, cyan, halogen, haloalkyl, carbonyl, nitro, carboxyl, C1-C5 alkoxy, substituted or unsubstituted C1-C10 straight-chain or branched alkyl , substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted amine, substituted or unsubstituted C5-C20 aryl, or substituted or unsubstituted C5-C20 heteroaryl, and two or more adjacent groups are may be combined with each other to form a substituted or unsubstituted aromatic hydrocarbon ring, wherein the aromatic hydrocarbon ring is a C5-C10 heteroaryl ring containing 0, 1, 2 or 3 heteroatoms selected from N, O, S, or can form an aryl ring;
- substituted C1-C10 straight-chain or branched alkyl may optionally be partially unsaturated and is independently deuterium, halogen, cyan, nitro, carboxyl, substituted or unsubstituted amine, substituted or unsubstituted C5-C20 aryl or C5 which may be substituted with one or more substituents selected from -C20 heteroaryl, substituted or unsubstituted C3-C8 cycloalkyl;
- said substituted C3-C8 cycloalkyl is independently deuterium, halogen, cyan, nitro, carboxyl, substituted or unsubstituted amine, substituted or unsubstituted C5-C20 aryl or C5-C20 heteroaryl, C1-C5 alkoxy;
- One or more substituents selected from C1-C5 haloalkyl or two or more substituents that are the same or different from each other may be linked and substituted;
- substituted C5-C20 aryl or substituted C5-C20 heteroaryl is independently deuterium, halogen, cyan, nitro, carboxyl, substituted or unsubstituted amine, C1-C5 alkoxy, C1-C5 haloalkyl, C1-C10 one or more substituents selected from alkyl, C3-C8 cycloalkyl, C1-C10 alkyl, C5-C20 aryl, C1-C10 alkyl, or two or more identical or different substituents may be linked and substituted;
- the substituted amine may be substituted with one or two C1-C5 alkyl groups
- the substituted C5-C10 arylene may be substituted by one or more substituents selected from C1-C3 alkyl, halogen, cyan, amine, nitro, and deuterium, or two or more substituents that are the same or different from each other.
- formula (I) is represented by the following formula (I-1).
- X is NR3
- R3 is selected from Ra-L-, Ra-L-CO-, Ra-L-NHCO-, Ra-L-OCO-, Ra-L-SO 2 -;
- Ra is hydrogen, deuterium, cyan, halogen, nitro, haloalkyl, substituted or unsubstituted C1-C10 straight chain or branched alkyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted C5-C20 aryl, or substituted or unsubstituted C5-C20 heteroaryl, said heteroaryl containing 1, 2 or 3 heteroatoms of O, N, S;
- L is selected from a direct bond, C1-C5 alkylene, substituted or unsubstituted C5-C10 arylene;
- R4 is selected from hydrogen or substituted or unsubstituted C1-C10 alkyl
- A is CR5 or N
- B is CR6 or N
- D is CR7 or N
- E is CR8 or N
- G is CR9 or N;
- R5 to R9 are the same or different, and each independently hydrogen, deuterium, cyan, halogen, haloalkyl, carbonyl, nitro, carboxyl, C1-C5 alkoxy, substituted or unsubstituted C1-C10 straight-chain or branched alkyl , substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted amine, substituted or unsubstituted C5-C20 aryl, or substituted or unsubstituted C5-C20 heteroaryl, and two or more adjacent groups are may be combined with each other to form a substituted or unsubstituted aromatic hydrocarbon ring, wherein the aromatic hydrocarbon ring is a C5-C10 heteroaryl ring containing 0, 1, 2 or 3 heteroatoms selected from N, O, S, or can form an aryl ring;
- substituted C1-C10 straight-chain or branched alkyl may optionally be partially unsaturated and is independently deuterium, halogen, cyan, nitro, carboxyl, substituted or unsubstituted amine, substituted or unsubstituted C5-C20 aryl or C5 which may be substituted with one or more substituents selected from -C20 heteroaryl, substituted or unsubstituted C3-C8 cycloalkyl;
- said substituted C3-C8 cycloalkyl is independently deuterium, halogen, cyan, nitro, carboxyl, substituted or unsubstituted amine, substituted or unsubstituted C5-C20 aryl or C5-C20 heteroaryl, C1-C5 alkoxy;
- One or more substituents selected from C1-C5 haloalkyl or two or more substituents that are the same or different from each other may be linked and substituted;
- substituted C5-C20 aryl or substituted C5-C20 heteroaryl is independently deuterium, halogen, cyan, nitro, carboxyl, substituted or unsubstituted amine, C1-C5 alkoxy, C1-C5 haloalkyl, C1-C10 one or more substituents selected from alkyl, C3-C8 cycloalkyl, C1-C10 alkyl, C5-C20 aryl, C1-C10 alkyl, or two or more identical or different substituents may be linked and substituted;
- the substituted amine may be substituted with one or two C1-C5 alkyl groups
- the substituted C5-C10 arylene may be substituted by one or more substituents selected from C1-C3 alkyl, halogen, cyan, amine, nitro, and deuterium, or two or more substituents that are the same or different from each other.
- formula (I) is represented by the following formula (I-2).
- Y is NR3
- R3 is selected from Ra-L-, Ra-L-CO-, Ra-L-NHCO-, Ra-L-OCO-, Ra-L-SO 2 -;
- Ra is hydrogen, deuterium, cyan, halogen, nitro, haloalkyl, substituted or unsubstituted C1-C10 straight chain or branched alkyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted C5-C20 aryl, or substituted or unsubstituted C5-C20 heteroaryl, said heteroaryl containing 1, 2 or 3 heteroatoms of O, N, S;
- L is selected from a direct bond, C1-C5 alkylene, substituted or unsubstituted C5-C10 arylene;
- R4 is selected from hydrogen or substituted or unsubstituted C1-C10 alkyl
- A is CR5 or N
- B is CR6 or N
- D is CR7 or N
- E is CR8 or N
- G is CR9 or N;
- R5 to R9 are the same or different, and each independently hydrogen, deuterium, cyan, halogen, haloalkyl, carbonyl, nitro, carboxyl, C1-C5 alkoxy, substituted or unsubstituted C1-C10 straight-chain or branched alkyl , substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted amine, substituted or unsubstituted C5-C20 aryl, or substituted or unsubstituted C5-C20 heteroaryl, and two or more adjacent groups are may be combined with each other to form a substituted or unsubstituted aromatic hydrocarbon ring, wherein the aromatic hydrocarbon ring is a C5-C10 heteroaryl ring containing 0, 1, 2 or 3 heteroatoms selected from N, O, S, or can form an aryl ring;
- substituted C1-C10 straight-chain or branched alkyl may optionally be partially unsaturated and is independently deuterium, halogen, cyan, nitro, carboxyl, substituted or unsubstituted amine, substituted or unsubstituted C5-C20 aryl or C5 which may be substituted with one or more substituents selected from -C20 heteroaryl, substituted or unsubstituted C3-C8 cycloalkyl;
- said substituted C3-C8 cycloalkyl is independently deuterium, halogen, cyan, nitro, carboxyl, substituted or unsubstituted amine, substituted or unsubstituted C5-C20 aryl or C5-C20 heteroaryl, C1-C5 alkoxy;
- One or more substituents selected from C1-C5 haloalkyl or two or more substituents that are the same or different from each other may be linked and substituted;
- substituted C5-C20 aryl or substituted C5-C20 heteroaryl is independently deuterium, halogen, cyan, nitro, carboxyl, substituted or unsubstituted amine, C1-C5 alkoxy, C1-C5 haloalkyl, C1-C10 one or more substituents selected from alkyl, C3-C8 cycloalkyl, C1-C10 alkyl, C5-C20 aryl, C1-C10 alkyl, or two or more identical or different substituents may be linked and substituted;
- the substituted amine may be substituted with one or two C1-C5 alkyl groups
- the substituted C5-C10 arylene may be substituted by one or more substituents selected from C1-C3 alkyl, halogen, cyan, amine, nitro, and deuterium, or two or more substituents that are the same or different from each other.
- R3 is Ra-L-
- L is a direct bond, selected from C1-C3 alkylene
- N of A, B, D, E, G is 0 or 1;
- R5 to R9 are the same or different, and each independently hydrogen, deuterium, cyan, halogen, haloalkyl, carbonyl, nitro, carboxyl, C1-C5 alkoxy, C1-C5 alkyl, one or more halogen substituted C1-C5 2 adjacent to each other selected from haloalkyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted amine, substituted or unsubstituted C5-C10 aryl, or substituted or unsubstituted C5-C10 heteroaryl More than one group may combine with each other to form a substituted or unsubstituted aromatic hydrocarbon ring, wherein the aromatic hydrocarbon ring is a C5-C10 heteroaryl containing 0, 1, 2 or 3 heteroatoms selected from N, O, and S. may form a ring or an aryl ring;
- R4 may be selected from hydrogen or substituted or unsubstituted C1-C5 alkyl.
- R3 is Ra-L-CO-
- L is selected from a direct bond, C1-C3 alkylene, substituted phenylene;
- N of A, B, D, E, G is 0 or 1;
- R5 to R9 are the same or different, and each independently hydrogen, deuterium, cyan, halogen, haloalkyl, carbonyl, nitro, carboxyl, C1-C5 alkoxy, C1-C5 alkyl, one or more halogen substituted C1-C5 2 adjacent to each other selected from haloalkyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted amine, substituted or unsubstituted C5-C10 aryl, or substituted or unsubstituted C5-C10 heteroaryl More than one group may combine with each other to form a substituted or unsubstituted aromatic hydrocarbon ring, wherein the aromatic hydrocarbon ring is a C5-C10 heteroaryl containing 0, 1, 2 or 3 heteroatoms selected from N, O, and S. may form a ring or an aryl ring;
- R4 may be selected from hydrogen or substituted or unsubstituted C1-C5 alkyl.
- R3 is Ra-L-NHCO-
- L is a direct bond, selected from C1-C3 alkylene
- N of A, B, D, E, G is 0 or 1;
- R5 to R9 are the same or different, and each independently hydrogen, deuterium, cyan, halogen, haloalkyl, carbonyl, nitro, carboxyl, C1-C5 alkoxy, C1-C5 alkyl, one or more halogen substituted C1-C5 2 adjacent to each other selected from haloalkyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted amine, substituted or unsubstituted C5-C10 aryl, or substituted or unsubstituted C5-C10 heteroaryl More than one group may combine with each other to form a substituted or unsubstituted aromatic hydrocarbon ring, wherein the aromatic hydrocarbon ring is a C5-C10 heteroaryl containing 0, 1, 2 or 3 heteroatoms selected from N, O, and S. may form a ring or an aryl ring;
- R4 may be selected from hydrogen or substituted or unsubstituted C1-C5 alkyl.
- R3 is Ra-L-OCO-
- L is a direct bond, selected from C1-C3 alkylene
- N of A, B, D, E, G is 0 or 1;
- R5 to R9 are the same or different, and each independently hydrogen, deuterium, cyan, halogen, haloalkyl, carbonyl, nitro, carboxyl, C1-C5 alkoxy, C1-C5 alkyl, one or more halogen substituted C1-C5 2 adjacent to each other selected from haloalkyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted amine, substituted or unsubstituted C5-C10 aryl, or substituted or unsubstituted C5-C10 heteroaryl More than one group may combine with each other to form a substituted or unsubstituted aromatic hydrocarbon ring, wherein the aromatic hydrocarbon ring is a C5-C10 heteroaryl containing 0, 1, 2 or 3 heteroatoms selected from N, O, and S. may form a ring or an aryl ring;
- R4 may be selected from hydrogen or substituted or unsubstituted C1-C5 alkyl.
- R3 is Ra-L-SO 2 -
- L is a direct bond, selected from C1-C3 alkylene
- N of A, B, D, E, G is 0 or 1;
- R5 to R9 are the same or different, and each independently hydrogen, deuterium, cyan, halogen, haloalkyl, carbonyl, nitro, carboxyl, C1-C5 alkoxy, C1-C5 alkyl, one or more halogen substituted C1-C5 2 adjacent to each other selected from haloalkyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted amine, substituted or unsubstituted C5-C10 aryl, or substituted or unsubstituted C5-C10 heteroaryl More than one group may combine with each other to form a substituted or unsubstituted aromatic hydrocarbon ring, wherein the aromatic hydrocarbon ring is a C5-C10 heteroaryl containing 0, 1, 2 or 3 heteroatoms selected from N, O, and S. may form a ring or an aryl ring;
- R4 may be selected from hydrogen or substituted or unsubstituted C1-C5 alkyl.
- the compound of Formula I may be any one of the following compounds.
- Furan-2-yl (3-hydroxy-2- (pyridin-2-yl) -2,4,5,7-tetrahydro-6H-pyrazolo [3,4-c] pyridin-6-yl) meta rice paddy;
- the compound of the present invention is PMA, TGF- ⁇ 1, palmitate or high concentration in all of NHLF (normal human lung fibroblast), LX-2 (human hepatic stellate), ARPE19 (human retinal pigment epithelial), and KEL-FIB (keloid fibroblast) cells-
- NHLF normal human lung fibroblast
- LX-2 human hepatic stellate
- ARPE19 human retinal pigment epithelial
- KEL-FIB keloid fibroblast
- cancer associated fibroblasts As fibroblasts differentiate into myofibroblasts, it has been reported that cancer associated fibroblasts (CAFs) are formed or that fibrosis of various tissues is induced.
- CAFs cancer associated fibroblasts
- the compounds of the present invention in HFF-1, LX-2, NHLF, ARPE19, and KEL-FIB cells induced by TGF- ⁇ 1 treatment the expression of ⁇ SMA, an indicator of fibrosis, was suppressed.
- the compound of the present invention can be used for the prevention or treatment of diseases related to fibrosis, and can be used for the treatment of cancer through modulation of cancer-associated fibroblasts, which are important indicators for the interaction of tumor microenvironment.
- the compound of the present invention can be used for the prevention or treatment of diseases related to neuronal cell death due to oxidative stress.
- One of the main causes of skin fibrotic disease is the production of extracellular matrix such as collagen type I by CTGF from keloid fibroblasts.
- CTGF extracellular matrix
- KEL-FIB keloid fibroblast
- IL-1 ⁇ is a cytokine associated with representative inflammatory diseases. After the LX-2 and NHLF cells were treated with LPS, when the compound of Synthesis Example was treated, the expression of IL-1b was effectively inhibited. Accordingly, the compounds of the present invention can be used for the prevention or treatment of inflammatory diseases.
- the compound of the present invention not only inhibits the expression of ⁇ SMA and Collagen I, which are indicators of lung fibrosis, in a mouse model of lung fibrosis, but also improves pulmonary fibrosis, such as lowering the infiltration of inflammatory cells into the alveoli and bronchiole. The effect was confirmed.
- the compound of the present invention effectively improved pulmonary fibrosis compared to nintedanib, which is used as a conventional treatment for idiopathic pulmonary fibrosis.
- the compounds of the present invention can be used for the prevention or treatment of fibrotic diseases including pulmonary fibrosis.
- the compound of the present invention showed improvement in liver fibrosis and hepatitis symptoms in non-alcoholic steatohepatitis and fibrosis-induced STAM mice. Therefore, the compound of the synthesis example of the present invention can be used for the prevention or treatment of liver disease including nonalcoholic hepatitis or liver fibrosis.
- the compound of the present invention improved the behavioral disorder symptoms of Parkinson's model mice, and improved the aggregation and accumulation of a-synuclein in brain tissue by 50% or more. Accordingly, the compound of the present invention can be used for the prevention or treatment of neurodegenerative diseases such as Parkinson's disease.
- the pharmaceutical composition of the present invention may be for treating a disease associated with oxidative stress.
- the disease may be cancer, an inflammatory disease, a fibrotic disease, a neurodegenerative disease, a liver disease, a skin disease, or a retinal disease.
- the cancer is, liver cancer, hepatocellular carcinoma, gastrointestinal cancer, gastric cancer, neurofibromatosis-associated meningioma, pancreatic cancer, leukemia, myeloproliferative/myelodysplastic disease, dermal fibrosarcoma, breast cancer, lung cancer, thyroid cancer, colon cancer, prostate cancer, It may be selected from the group consisting of breast cancer, ovarian cancer, brain tumor, head and neck cancer, glioblastoma, and the like.
- the cancer may be a secondary cancer that has metastasized to another organ from the above various types of cancer.
- the inflammatory disease is rheumatoid arthritis, osteoarthritis, pneumonia, hepatitis, inflammatory bowel disease, enteroenteritis, glomerulonephritis, gastritis, vasculitis, pancreatitis, peritonitis, bronchitis, cardiomyositis, encephalitis, postischemic reperfusion Inflammation in injury), inflammation occurring in immune rejection after tissue and organ transplantation, burns, allergic contact dermatitis, various inflammations occurring in the skin, inflammation occurring in multiple organ disorders, including diabetic nephropathy It may be diabetic inflammation, infectious inflammation due to a viral or bacterial infection, or an autoimmune disease such as lupus, psoriasis, or atherosclerosis.
- the fibrotic disease is metabolic disease-induced liver fibrosis or cirrhosis, NAFLD-induced fibrosis or cirrhosis, NASH-induced fibrosis or cirrhosis, alcohol-induced liver fibrosis or cirrhosis, drug-induced liver fibrosis or cirrhosis, infectious agent-induced liver fibrosis or cirrhosis, parasitic infection-induced liver fibrosis or cirrhosis, bacterial infection-induced liver fibrosis or cirrhosis, viral infection-induced fibrosis or cirrhosis, HBV infection-induced liver fibrosis or cirrhosis, HCV infection-induced liver fibrosis or cirrhosis, HIV-infection induced liver fibrosis or cirrhosis, dual HCV and HIV-infection induced liver fibrosis or cirrhosis, radiation- or chemotherapy-induced fibrosis or cirrhosis, biliary tract fibrosis, liver fibrosis
- the neurodegenerative disease is Alzheimer's disease (mild or early Alzheimer's disease, mild to moderate Alzheimer's disease, moderate or intermediate Alzheimer's disease, moderate to severe Alzheimer's disease, moderately severe Alzheimer's disease, severe Alzheimer's disease, Alzheimer's with Lewy bodies) disease (AD)), Parkinson's disease (chemically induced by exposure to environmental agents such as pesticides, insecticides, or herbicides and/or metals such as manganese, aluminum, cadmium, copper, or zinc) Parkinson's disease, including SNCA gene-associated Parkinson's disease, sporadic or idiopathic Parkinson's disease, or Parkinson's- or LRRK2-associated Parkinson's disease (PD), autosomal dominant Parkinson's disease, Diffuse Lewy Body Disease (DLBD) ) (also known as Dementia with Lewy Bodies (DLB)), pure autonomic dysphagia, Lewy body dysphagia, accidental LBD, genetic LBD (e.g., mutations in the alpha-
- Liver disease is metabolic liver disease, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), drug-induced liver disease, alcohol-induced liver disease, infectious agent-induced liver disease, inflammatory liver disease, immune system dysfunction- mediated liver disease, or dyslipidemia.
- NAFLD non-alcoholic fatty liver disease
- NASH non-alcoholic steatohepatitis
- drug-induced liver disease alcohol-induced liver disease
- infectious agent-induced liver disease infectious agent-induced liver disease
- inflammatory liver disease inflammatory liver disease
- immune system dysfunction- mediated liver disease or dyslipidemia.
- the skin disease may be keloid disease, psoriasis, or Banbanism
- the retinal disease may be retinal fibrosis, macular degeneration, diabetic retinopathy, cataract or neovascular glaucoma.
- the compounds of the present invention may be in the form of pharmaceutically acceptable salts thereof.
- the salt means a salt commonly used in the pharmaceutical industry to which the present invention belongs, and may be, for example, an inorganic acid salt prepared with hydrochloric acid, nitric acid, phosphoric acid, hydrobromic acid, iodic acid, perchloric acid, tartaric acid and sulfuric acid.
- It may be an organic acid salt prepared with acid, ascorbic acid, carbonic acid, or the like.
- salts derived from metals such as lithium, sodium, potassium, magnesium, or calcium.
- it may be a sulfonic acid prepared from methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, naphthalenesulfonic acid, etc., and the types of salts in the present invention are limited by these listed salts. no.
- the compounds of the present invention may also be in the form of their solvates.
- “Solvate” means a complex or aggregate formed by one or more solute molecules, ie a compound of formula (I), or a pharmaceutically acceptable salt thereof, and one or more solvent molecules.
- Solvates may be complexes or aggregates formed with various solvent molecules, such as, for example, water, methanol, ethanol, isopropanol or acetic acid.
- the compounds of the present invention may also be in the form of their stereoisomers.
- the stereoisomer includes all stereoisomers such as enantiomers and diastereomers.
- the compound may be in a stereoisomerically pure form or a mixture of one or more stereoisomers, for example a racemic mixture. Separation of specific stereoisomers can be carried out by one of the conventional methods known in the art. Some examples of the compound of the present invention may have a greater inhibitory effect on oxidative stress of a specific stereoisomer than that of the racemic mixture. In this case, the dosage can be reduced by using a specific stereoisomer. Accordingly, by separating a specific stereoisomer having a large inhibitory effect on oxidative stress, for example, an enantiomer or a diastereomer, it is possible to efficiently treat a disease related to oxidative stress.
- Another aspect of the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) as defined above, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof and a pharmaceutically acceptable carrier.
- the compound, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof is as described above.
- composition of the present invention refers to a substance used in combination with an active ingredient, generally an inert substance, to aid in the application of the active ingredient.
- the carrier includes conventional pharmaceutically acceptable excipients, additives or diluents.
- the carrier may be, for example, a filler, a binder, a disintergrant, a buffer, a preservative, an antioxidant, a glidant, a flavoring agent, a thickener, a coloring agent, an emulsifier, a suspending agent. It may include one or more selected from an agent, a stabilizing agent, a pH adjusting agent, and an isotonic agent.
- the diluent may be sugar, starch, microcrystalline cellulose, lactose (lactose hydrate), glucose, di-mannitol, alginate, alkaline earth metal salts, clay, polyethylene glycol, anhydrous calcium hydrogen phosphate, or mixtures thereof;
- the binder is starch, microcrystalline cellulose, highly dispersible silica, mannitol, di-mannitol, sucrose, lactose hydrate, polyethylene glycol, polyvinylpyrrolidone (povidone), polyvinylpyrrolidone copolymer (copovidone), hyprobellose. , hydroxypropyl cellulose, natural gum, synthetic gum, gelatin, or a mixture thereof may be used.
- the disintegrant is starch or modified starch such as sodium starch glycolate, corn starch, potato starch, pregelatinized starch; clays such as bentonite, montmorillonite or veegum; celluloses such as microcrystalline cellulose, hydroxypropyl cellulose or carboxymethyl cellulose; algins such as sodium alginate or alginic acid; cross-linked celluloses such as croscarmellose sodium; gums such as guar gum and xanthan gum; crosslinked polymers such as crosslinked polyvinylpyrrolidone (crospovidone); Effervescent agents such as sodium bicarbonate and citric acid or mixtures thereof may be used.
- starch or modified starch such as sodium starch glycolate, corn starch, potato starch, pregelatinized starch
- clays such as bentonite, montmorillonite or veegum
- celluloses such as microcrystalline cellulose, hydroxypropyl cellulose or carboxymethyl cellulose
- algins such as
- Lubricants include talc, stearic acid, magnesium stearate, calcium stearate, sodium lauryl sulfate, hydrogenated vegetable oil, sodium benzoate, sodium stearyl fumarate, glyceryl monorate, glyceryl monostearate, glyceryl palmitostearate, colloidal Silicon dioxide or a mixture thereof may be used.
- pH adjusters include acidifying agents such as acetic acid, ascorbic acid, sodium ascorbate, sodium etherate, malic acid, succinic acid, tartaric acid, fumaric acid, citric acid (citric acid) and precipitated calcium carbonate, aqueous ammonia, meglumine, sodium carbonate, magnesium oxide , basifying agents such as magnesium carbonate, sodium citrate, tribasic calcium phosphate, and the like can be used.
- acidifying agents such as acetic acid, ascorbic acid, sodium ascorbate, sodium etherate, malic acid, succinic acid, tartaric acid, fumaric acid, citric acid (citric acid) and precipitated calcium carbonate, aqueous ammonia, meglumine, sodium carbonate, magnesium oxide , basifying agents such as magnesium carbonate, sodium citrate, tribasic calcium phosphate, and the like can be used.
- the solubilizing agent may include polyoxyethylene sorbitan fatty acid esters such as sodium lauryl sulfate and polysorbate, sodium docusate, poloxamer, and the like.
- it may include an enteric polymer, a water-insoluble polymer, a hydrophobic compound, and a hydrophilic polymer to make a delayed-release preparation.
- the enteric polymer is insoluble or stable under acidic conditions of less than pH 5, and refers to a polymer that is dissolved or decomposed under a specific pH condition of pH 5 or higher, for example, hypromellose acetate succinate, hypromellose phthalate.
- the water-insoluble polymer refers to a pharmaceutically acceptable water-insoluble polymer that controls the release of the drug.
- water-insoluble polymers include polyvinylacetate (e.g., Colicot SR30D), water-insoluble polymethacrylate copolymers (e.g., poly(ethylacrylate-methyl methacrylate) copolymer (e.g., For example, Eudragit NE30D, poly(ethyl acrylate-methyl methacrylate-trimethylaminoethyl methacrylate) copolymer (eg Eudragit RSPO), etc.], ethyl cellulose, cellulose ester, cellulose ether, cellulose acylate, cellulose diacylate, cellulose triacylate, cellulose acetate, cellulose diacetate and cellulose triacetate.
- polyvinylacetate e.g., Colicot SR30D
- water-insoluble polymethacrylate copolymers e.g.,
- the hydrophobic compound refers to a pharmaceutically acceptable water-insoluble substance that controls the release of the drug.
- fatty acids and fatty acid esters such as glyceryl palmitostearate, glyceryl stearate, glyceryl bihenate, cetyl palmitate, glyceryl monooleate and stearic acid
- fatty acid alcohols such as cetostearyl alcohol, cetyl alcohol and stearyl alcohol
- waxes such as carnauba wax, beeswax, and microcrystalline wax
- inorganic substances such as talc, precipitated calcium carbonate, calcium monohydrogen phosphate, zinc oxide, titanium oxide, kaolin, bentonite, montmorillonite, and veegum.
- the hydrophilic polymer refers to a pharmaceutically acceptable water-soluble polymer material that controls the release of a drug.
- Eudragit E100, Evonik, Germany poly(ethyl acrylate-methyl methacrylic hydrophilic polymethacrylate copolymers such as Raid-triethylaminoethyl-methacrylate chloride) copolymers (eg Eudragit RL, RS, Evonik, Germany); polyethylene glycol, and polyethylene derivatives such as polyethylene oxide; Carbomer, etc.
- formulation of the present invention may be formulated by selecting pharmaceutically acceptable additives as various additives selected from colorants and fragrances.
- the scope of the additive is not limited to using the additive, and the additive may be selected and formulated to contain a dose within a normal range.
- the pharmaceutical composition according to the present invention may be formulated in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups and aerosols, external preparations, suppositories, or sterile injection solutions according to conventional methods. there is.
- composition of the present invention may be administered orally or parenterally, including intravenous, intraperitoneal, subcutaneous, rectal and topical administration.
- Another aspect of the invention provides a method of treating a disease in a subject comprising administering to the subject a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate or stereoisomer thereof .
- parenteral administration includes intravenous, intraperitoneal, subcutaneous, rectal and topical administration.
- the dosage may be variously changed according to various factors such as the patient's condition, administration route, judgment of the attending physician, and the like, as described above.
- An effective dosage can be estimated from a dose-response curve obtained from in vitro experiments or animal model studies.
- the proportion and concentration of the compound of the present invention present in the composition to be administered may depend on the chemical nature, route of administration, therapeutic dosage, and the like.
- the dosage may be administered to an individual in an effective amount of about 1 ⁇ g/kg to about 1 g/kg/day, or about 0.1 mg/kg to about 500 mg/kg/day.
- the dose may be changed according to the age, weight, susceptibility, or symptoms of the individual.
- the pharmaceutical composition comprising the compound or solvate, stereoisomer or pharmaceutically acceptable salt thereof of the present invention as an active ingredient is cancer, keloidosis, liver fibrosis, comprising administering to an individual in need thereof.
- Parkinson's disease Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, ischemic or traumatic brain injury, retinal fibrosis, macular degeneration, can be used in a method of preventing or treating a disease selected from inflammatory diseases.
- the compound represented by Formula I of the present invention may be prepared by the method exemplified in the following scheme, but is not limited thereto.
- Synthesis Examples 1 to 4 were synthesized by the following method, and specific synthesis examples were described.
- Synthesis Examples 5 to 33, 35 to 38, 43, 44, 53 to 58, 65 to 70, 73, and 74 are synthesized according to the general reaction scheme above, and examples of the synthesis method to which specific compounds are applied are as follows.
- the reaction mixture solution was stirred at room temperature for 1 hour, and after confirming the completion of the reaction by LC-MS, 50 mL of ethyl acetate was added for dilution, and the mixture was washed with brine and a mixed saturated solution of NaHCO 3 .
- the product was separated and purified by preparative TLC and the yield ranged from 10 to 70%. Furthermore, the data of the synthesis example prepared according to the above general synthesis method and the synthesis method using specific materials were described.
- Ethyl 1-benzyl-3-oxo-4-piperidine-carboxylate hydrochloride (0.50 g, 1.68 mmol) and 5-chloro-2-hydrazino pyridine (0.24 g, 1.68 mmol) were dissolved in 10 mL of ethanol. Dissolve and add 2 drops of acetic acid. The reaction mixture was stirred at room temperature for 1 hour, sodium triacetoxyborohydride (0.53 g, 2.52 mmol) was added thereto, and then stirred for 30 hours. The reaction mixture was concentrated under reduced pressure and extracted with water and dichloromethane. The organic layer was dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The reaction mixture was recrystallized from ethyl acetate to obtain the title compound (0.12 g, 22 %).
- Synthesis Examples 34, 39 to 42, 45 to 52, 59 to 64, 71, 72, and 75 to 81 are synthesized according to the above general scheme, and examples of the synthesis method to which specific compounds are applied are as follows. Furthermore, the data of the synthesis example according to the above synthesis method were described.
- HL-60 cells differentiated into neutrophils through DMSO treatment (Korea Cell Line Bank), NHLF (normal human lung fibroblast, Lonza ), LX-2 (human hepatic stellate cells, Sigma), ARPE19 (human retinal pigment epithelial cell, ATCC), KEL-FIB (Keloid fibroblast, ATCC) cells, PMA (phorbol 12-myristate 13-acetate), TGF - ⁇ 1, palmitate, or high concentration- ROS generation was induced through stimulation such as glucose, and the ROS generation inhibitory effect of the compound of Synthesis Example was observed under these conditions.
- HL-60 cells human leukemia cells, ATCC
- a medium RPMI+10% FBS
- DMSO fetal bovine serum
- HL-60 cells differentiated into neutrophil cells were aliquoted in a 96-well plate at a concentration of 2x10 4 cells/well, and the compound of Synthesis Example was treated at a concentration of 0.5 mM in the cells for 30 minutes.
- the generation of ROS was induced by treating each well containing cells and drugs with 200 nM PMA, and the generation of ROS was measured by observing the luminescence level of each well using 100 ⁇ M L-012.
- NHLF normal human lung fibroblast, Lonza
- LX-2 human hepatic stellate cells, Sigma
- ARPE19 human retinal pigment epithelial cell, ATCC
- KEL-FIB keloid fibroblast, ATCC
- fibroblasts are differentiated into myofibroblasts to form cancer associated fibroblasts (CAFs) or induce fibrosis of various tissues.
- CAFs cancer associated fibroblasts
- HL-60 cells Kerat Cell Line Bank
- HFF-1 human foreskin fibroblast, ATCC
- NHLF normal TGF- ⁇ 1-induced ⁇ SMA in human lung fibroblast, Lonza
- LX-2 human hepatic stellate cells, Sigma
- ARPE19 human retinal pigment epithelial cell, ATCC
- KEL-FIB Kerat Cell, ATCC
- Each cell is suspended in DMEM medium containing 10% FBS and aliquoted on a 4-well chamber slide (Nunc) at a concentration of 1x10 4 cells/well, and the synthesis example compound and TGF- ⁇ 1 (TGF ⁇ 1, TGF- ⁇ are all the same meaning) to prepare cells for use in confirming ⁇ SMA expression. Confirmation of ⁇ SMA expression in the prepared cells was performed through immunocytochemistry as follows.
- ⁇ SMA anti- ⁇ SMA Ab, 1:200, 4° C for 16 hours
- secondary antibody Alexa-594 conjugated Ab, 1:800, 1 hour at room temperature
- FIG. 2 is an observation of the effect of ⁇ SMA expression in ARPE19 cells treated with TGF- ⁇ 1 (5 ⁇ M) treatment, and then treated with various synthesis example compounds (5 ⁇ M). Although the compounds of Synthesis Examples 3, 8, 9, and 26 have different degrees, all of them showed an effect of inhibiting ⁇ SMA expression by 35% to 70% or more.
- N27 cells were cultured in RPMI medium containing 10% FBS and 1 ⁇ M angiotensin II, and the cultured cells were seeded at a concentration of 5 x 10 3 ⁇ 6 x 10 3 cells/well in a 6 well plate.
- Cells were treated with MPP+ (1-methyl-4-phenylptridinium) and Synthesis Example compound 3 (1 ⁇ M), which are ROS production stimulants.
- Example 4 keloid fibroblast target, CTGF and COL1A1 gene expression change analysis
- KEL-FIB keloid fibroblast
- the KEL-FIB cell line was pre-treated with the compound of Synthesis Example 3 at a concentration of 5 ⁇ M or 10 ⁇ M for 1 hour after adaptation in DMEM containing 2% FBS for 24 hours. 2ng/ml TGF- ⁇ 1 was treated to induce expression of CTGF and collagen type I genes, and mRNA was extracted from the cells after 24 or 48 hours. The mRNA presence and expression level of CTGF and collagen type 1 genes were confirmed by qRT-PCR (quantitative real-time PCR).
- the expression of the CTGF gene and the collagen type I gene was increased by 26 and 2.3 times, respectively, by 2ng/ml TGF- ⁇ 1 treatment.
- the expression of both genes was 76 by treatment with 5 ⁇ M or 10 ⁇ M of Synthesis Example 3 compound. % and 75% were confirmed to be inhibited.
- the base sequence for the target primer is as follows.
- IL-1 ⁇ forward: 5'-CCACAGACCTTCCAGGAGAATG-3', reverse: 5'-GTGCAGTTCAGTGATCGTACAGG-3'
- GAPDH forward: 5'-GTGGCTGGCTCAGAAAAAGG-3', reverse: 5'-GTGGGTCCAGGGGTCTTACT-3'
- ⁇ -actin forward: 5'-CACCATTGGCAATGAGCGGTTC-3', reverse: 5'-AGGTCTTTGCGGATGTCCACGT-3'.
- mice C57BL/6J male mice aged 5 weeks and before and after body weight of 20 g were used.
- Experimental animals were treated with 7 animals in each group, a control group that was orally administered with distilled water (Control), a group that induced pulmonary fibrosis with bleomycin (BLM), and three weeks after administration of bleomycin, 100 mg/kg of nintedanib ( nintedanib) was administered orally daily (BLM + NIN), and 3 weeks after administration of bleomycin, 3 mg/kg of the compound of Synthesis Example of the present invention was orally administered daily (BLM + Synthesis example). proceeded.
- Nintedanib and the compound of Synthesis Example were orally administered once a day for 28 days.
- the next day after the last administration of nintedanib or a compound of the synthetic example each animal was anesthetized, blood was collected by cardiac puncture, and sacrificed, and BALF (broncho-alveolar lavage fluid) and lung tissue were isolated and used for additional tests.
- Cell staining, Hematoxylin & Eosin (H&E) staining, and Masson's trichrome (MT) staining to confirm fibrosis were performed, and the expression rates of ⁇ SMA and Collagen I in lung tissue were confirmed.
- H&E Hematoxylin & Eosin
- MT Masson's trichrome
- control negative control group
- experimental group experimental group
- BLM + positive control group
- PBS negative control group
- bleomycin induced lung fibrosis The experimental group (BLM) was 5.4 ⁇ 0.5.
- the improved Ashcroft score of the positive control group (BLM + NIN) was reduced to 5.0 ⁇ 0, and the improved Ashcroft score in the experimental group (BLM + Synthesis example) to which the compound of the Synthesis Example was administered was 3.44 ⁇ 0.88. It was confirmed that it effectively improved pulmonary fibrosis compared to nintedanib, which was used as a treatment for idiopathic pulmonary fibrosis.
- STAM mice (6 weeks old, female, SMC laborlabories Inc, Japan) induced in nonalcoholic steatohepatitis and fibrosis were used to confirm the therapeutic effect of the compound of the synthesis example of the present invention for nonalcoholic steatohepatitis and liver fibrosis. All mice were maintained under standard conditions. Experimental animals were treated with 10 mg/kg of telmisartane as a normal control group (negative control), which was orally administered with distilled water in 7 animals in each group, a non-alcoholic steatohepatitis and fibrosis induced STAM group (vehicle control), and a STAM positive control group.
- the experiment was carried out by dividing the experimental group (STAM + TEL) administered orally daily, and the experimental group (STAM + Synthesis Example) in which 3 or 10 mg/kg of the compound of Synthesis Example was orally administered daily. Telmisartan and the compound of Synthesis Example were orally administered once a day for 28 days.
- liver tissues were extracted for each individual, and blood was taken for examination. Liver tissue was weighed and photographed. Tissues were fixed in 10% buffered neutral formalin solution. After trimming the fixed tissue to a certain thickness, paraffin-embedded tissue sections of 4 to 5 ⁇ m are produced through general tissue processing, followed by Hematoxylin & Eosin (H&E stain) staining, which is a general staining method, and Sirius for confirmation of fibrosis. In order to confirm the red staining and the production of lipids, oil red O working solution staining was performed and histopathological findings were observed.
- H&E stain Hematoxylin & Eosin
- the liver fibrosis area was 0.29 ⁇ 0.06 in the normal control group showing normal findings, and 0.93 ⁇ 0.36 in the STAM experimental group (STAM + vehicle). . It was confirmed that the improved fibrosis area of the positive control group (STAM + TEL) was reduced to 0.44 ⁇ 0.15, and the improved fibrosis area of the experimental group (STAM + Synthesis example) to which the compound of Synthesis Example was administered was reduced to 0.49 ⁇ 0.16.
- a Parkinson's disease mouse (alpha-Synuclein A53T mutant transgenic mouse) model was established in order to test the effect of the compound of Synthesis to prevent or treat brain diseases or diseases.
- mice All mice were maintained under standard conditions. Experimental animals were divided into a normal control group (negative control), in which distilled water was orally administered to 8 animals in each group, Parkinson's disease induction group (vehicle control), and an experimental group (synthesis example) in which 25 mg/kg of the compound of Synthesis Example was orally administered daily. proceeded.
- the normal control group was administered with physiological saline, and the compound of Synthesis Example was orally administered once a day for 2 weeks, and then behavioral change experiments and histopathological experiments were performed.
- the animals were anesthetized, brain tissues were extracted for each individual, and the tissues were fixed in 4% neutral buffered formalin solution (10% buffered neutral formalin). After the fixed tissue was cut to a certain thickness, it was embedded in paraffin through a general tissue processing process to prepare tissue sections of 4-5 ⁇ m. Thereafter, in order to check whether the Parkinson's disease pathological index is improved according to the level of protein aggregation in the striatum, it is first labeled with phosphorylated- Serin-129 alpha-synuclein and then Thioflavin-T staining is performed to obtain histopathological findings. observed.
- the Parkinson-like behavioral symptoms were improved by more than 50%, and an important pathological condition of Parkinson's disease. It was observed that aggregation and accumulation of a-synuclein, an indicator, were improved by more than 50%.
Abstract
Description
구조 | ESI-MS[M+H]+ | 명칭 | |
1 | 216.1 | 2-(피리딘-2-일)-4,5,6,7-테트라하이드로-2H-인다졸-3-올 | |
2 | 284.1 | 2-(5-(트리플루오로메틸)피리딘-2-일)-4,5,6,7-테트라하이드로-2H-인다졸-3-올 | |
3 | 307.2 | 6-벤질-2-(피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올 | |
4 | 375.1 | 6-벤질-2-(5-(트리플루오로메틸)피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올 | |
5 | 217.1 | 2-(피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올 | |
6 | 325.1 | 6-(4-플루오로벤질)-2-(피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올 | |
7 | 321.2 | 6-(4-메틸벤질)-2-(피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올 | |
8 | 332.1 | 4-((3-하이드록시-2-(피리딘-2-일)-2,4,5,7-테트라하이드로-6H-피라졸로[3,4-c]피리딘-6-일)메틸)벤조나이트릴 | |
9 | 343.1 | 6-(3,5-다이플루오로벤질)-2-(피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올 | |
10 | 375.1 | 2-(피리딘-2-일)-6-(3-(트리플루오로메틸)벤질)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올 | |
11 | 357.2 | 6-(나프탈렌-2-일메틸)-2-(피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올 | |
12 | 287.1 | 1-(4,5-다이하이드로-3-하이드록시-2-(피리딘-2-일)-2H-피라졸로[3,4-c]피리딘-6(7H)-일)부탄-1-온 | |
13 | 259.1 | 1-(3-하이드록시-2-(피리딘-2-일)-2,4,5,7-테트라하이드로-6H-피라졸로[3,4-c]피리딘-6-일)에탄-1-온 | |
14 | 337.2 | 6-(4-메톡시벤질)-2-(피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올 | |
15 | 245.1 | 6-에틸-2-(피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올 | |
16 | 255.1 | 6-(프로프-2-인-1-일)-2(피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올 | |
17 | 259.2 | 6-프로필-2-(피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올 | |
18 | 257.1 | 6-알릴-2-(피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올 | |
19 | 321.1 | (3-하이드록시-2-(피리딘-2-일)-2,4,5,7-테트라하이드로-6H-피라졸로[3,4-c]피리딘-6-일)(페닐)메타논 | |
20 | 351.1 | 벤질 3-하이드록시-2-(피리딘-2-일)-2,4,5,7-테트라하이드로-6H-피라졸로[3,4-c]피리딘-6-카복실레이트 | |
21 | 355.1 | (4-클로로페닐)(3-하이드록시-2-(피리딘-2-일)-2,4,5,7-테트라하이드로-6H-피라졸로[3,4-c]피리딘-5-일)메타논 | |
22 | 289.1 | 에틸 3-하이드록시-2-(피리딘-2-일)-2,4,5,7-테트라하이드로-6H-피라졸로[3,4-c]피리딘-6-카복실레이트 | |
23 | 342.2 | N-사이클로헥실-3-하이드록시-2-(피리딘-2-일)-2,4,5,7-테트라하이드로-6H-피라졸로[3,4-c]피리딘-6-카복사마이드 | |
24 | 311.1 | 퓨란-2-일(3-하이드록시-2-(피리딘-2-일)-2,4,5,7-테트라하이드로-6H-피라졸로[3,4-c]피리딘-6-일)메타논 | |
25 | 295.1 | 6-(메틸술포닐)-2-(피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올 | |
26 | 357.1 | 6-(페닐술포닐)-2-(피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올 | |
27 | 354.1 | N-(4-플루오로페닐)-3-하이드록시-2-(피리딘-2-일)-2,4,5,7-테트라하이드로-6H-피라졸로[3,4-c]피리딘-6-카복사마이드 | |
28 | 368.1 | N-(4-플루오로벤질)-3-하이드록시-2-(피리딘-2-일)-2,4,5,7-테트라하이드로-6H-피라졸로[3,4-c]피리딘-6-카복사마이드 | |
29 | 340.1 | N-(퓨란-2-일메틸)-3-하이드록시-2-(피리딘-2-일)-2,4,5,7-테트라하이드로-6H-피라졸로[3,4-c]피리딘-6-카복사마이드 | |
30 | 398.1 | N-(4-클로로페네틸)-3-하이드록시-2-(피리딘-2-일)-2,4,5,7-테트라하이드로-6H-피라졸로[3,4-c]피리딘-6-카복사마이드 | |
31 | 407.1 | 6-(나프탈렌-2-일술포닐)-2-(피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올 | |
32 | 396.1 | 4-나이트로벤질 3-하이드록시-2-(피리딘-2-일)-2,4,5,7-테트라하이드로-6H-피라졸로[3,4-c]피리딘-6-카복실레이트 | |
33 | 459.2 | (5-(4-사이클로프로필-1H-이미다졸-1-일)-2-플루오로-4-메틸페닐)(3-하이드록시-2-(피리딘-2-일)-2,4,5,7-테트라하이드로-6H-피라졸로[3,4-c]피리딘-6-일)메타논 | |
34 | 307.2 | 5-벤질-2-(피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[4,3-c]피리딘-3-올 | |
35 | 341.1 | 6-벤질-2-(5-클로로피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올 | |
36 | 350.1 | 4-(6-벤질-3-하이드록시-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-2-일)벤조산 | |
37 | 384.1 | 6-벤질-2-(4-브로모페닐)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올 | |
38 | 306.2 | 6-벤질-2-페닐-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올 | |
39 | 375.1 | 5-벤질-2-(5-트리플루오로메틸)피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[4,3-c]피리딘-3-올 | |
40 | 306.2 | 5-벤질-2-페닐-4,5,6,7-테트라하이드로-2H-피라졸로[4,3-c]피리딘-3-올 | |
41 | 384.1 | 5-벤질-2-(4-브로모페닐)-4,5,6,7-테트라하이드로-2H-피라졸로[4,3-c]피리딘-3-올 | |
42 | 340.1 | 5-벤질-2-(2-클로로페닐)-4,5,6,7-테트라하이드로-2H-피라졸로[4,3-c]피리딘-3-올 | |
43 | 340.1 | 6-벤질-2-(2-클로로페닐)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올 | |
44 | 336.2 | 6-벤질-2-(2-메톡시페닐)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올 | |
45 | 341.1 | 5-벤질-2-(5-클로로피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[4,3-c]피리딘-3-올 | |
46 | 389.2 | 5-벤질-2-(6-메틸-4-(트리플루오로메틸)피리딘-2-일)- 4,5,6,7-테트라하이드로-2H-피라졸로[4,3-c]피리딘-3-올 | |
47 | 363.1 | 5-벤질-2-(티에노[3,2-c]피리딘-4-일)-4,5,6,7-테트라하이드로-2H-피라졸로[4,3-c]피리딘-3-올 | |
48 | 357.2 | 5-(나프탈렌-2-일메틸)-2-(피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[4,3-c]피리딘-3-올 | |
49 | 425.1 | 5-(나프탈렌-2-일메틸)-2-(5-(트리플루오로메틸)피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[4,3-c]피리딘-3-올 | |
50 | 443.1 | 5-(3-(트리플루오로메틸)벤질)-2-(5-(트리플루오로메틸)피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[4,3-c]피리딘-3-올 | |
51 | 343.1 | 5-(3,5-다이플루오로벤질)-2-(피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[4,3-c]피리딘-3-올 | |
52 | 411.1 | 5-(3,5-다이플루오로벤질)-2-(5-트리플루오로메틸)피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[4,3-c]피리딘-3-올 | |
53 | 321.2 | 6-벤질-3-메톡시-2-(피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘 | |
54 | 332.1 | 6-(6-벤질-3-하이드록시-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-2-일)니코티노나이트릴 | |
55 | 375.1 | 6-벤질-2-(6-(트리플루오로메틸)피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올 | |
56 | 325.1 | 6-벤질-2-(3-플루오로피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올 | |
57 | 321.2 | 6-벤질-2-(6-메틸피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올 | |
58 | 389.2 | 6-벤질-2-(6-메틸-4-(트리플루오로메틸)피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올 | |
59 | 321.2 | 5-벤질-2-(6-메틸피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[4,3-c]피리딘-3-올 | |
60 | 375.1 | 5-벤질-2-(6-트리플루오로메틸)피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[4,3-c]피리딘-3-올 | |
61 | 332.1 | 6-(5-벤질-3-하이드록시-4,5,6,7-테트라하이드로-2H-피라졸로[4,3-c]피리딘-2-일)니코티노나이트릴 | |
62 | 325.1 | 5-벤질-2-(3-플루오로피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[4,3-c]피리딘-3-올 | |
63 | 363.1 | 5-벤질-2-(티에노[3,2-c]피리딘-4-일)-4,5,6,7-테트라하이드로-2H-피라졸로[4,3-c]피리딘-3-올 | |
64 | 389.2 | 5-벤질-2-(6-메틸-4-(트리플루오로메틸)피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[4,3-c]피리딘-3-올 | |
65 | 363.1 | 6-벤질-2-(티에노[3,2-c]피리딘-4-일)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올 | |
66 | 308.1 | 2-(피리딘-2-일)-6-(피리딘-2-일메틸)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올 | |
67 | 308.1 | 2-(피리딘-2-일)-6-(피리딘-4-일메틸)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올 | |
68 | 350.2 | 6-(4-(다이메틸아미노)벤질)-2-(피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올 | |
69 | 350.2 | 6-(3-(다이메틸아미노)벤질)-2-(피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올 | |
70 | 322.2 | 2-(6-아미노피리딘-2-일)-6-벤질-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올 | |
71 | 350.2 | 5-(4-(다이메틸아미노)벤질)-2-(피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[4,3-c]피리딘-3-올 | |
72 | 350.2 | 5-(3-(다이메틸아미노)벤질)-2-(피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[4,3-c]피리딘-3-올 | |
73 | 358.2 | 2-(피리딘-2-일)-6-(퀴놀린-6-일메틸)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올 | |
74 | 358.2 | 6-(이소퀴놀린-3-일메틸)-2-(피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올 | |
75 | 332.1 | 4-((3-하이드록시-2-(피리딘-2-일)-2,4,6,7-테트라하이드로-5H-피라졸로[4,3-c]피리딘-5-일)메틸)벤조나이트릴 | |
76 | 400.1 | 4-((3-하이드록시-2-(5-(트리플루오로메틸)피리딘-2-일)-2,4,6,7-테트라하이드로-5H-피라졸로[4,3-c]피리딘-5-일)메틸)벤조나이트릴 | |
77 | 375.1 | 2-(피리딘-2-일)-5-(3-(트리플루오로메틸)벤질)-4,5,6,7-테트라하이드로-2H-피라졸로[4,3-c]피리딘-3-올 | |
78 | 443.1 | 5-(3-(트리플루오로메틸)벤질)-2-(5-(트리플루오로메틸)피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[4,3-c]피리딘-3-올 | |
79 | 358.2 | 5-(이소퀴놀린-3-일메틸)-2-(피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[4,3-c]피리딘-3-올 | |
80 | 426.2 | 5-(이소퀴놀린-3-일메틸)-2-(5-(트리플루오로메틸)피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[4,3-c]피리딘-3-올 | |
81 | 350.1 | 4-(5-벤질-3-하이드록시-4,5,6,7-테트라하이드로-2H-피라졸로[4,3-c]피리딘-2-일)벤조산 |
합성예 번호 | ROS 생성 억제 효과 |
1 | * |
2 | * |
3 | *** |
4 | ** |
6 | ** |
7 | ** |
8 | *** |
9 | *** |
10 | ** |
15 | * |
16 | * |
23 | * |
26 | *** |
32 | ** |
34 | ** |
35 | *** |
36 | **** |
37 | **** |
38 | **** |
39 | * |
40 | *** |
41 | *** |
42 | * |
50 | ** |
75 | *** |
76 | ** |
77 | ** |
78 | *** |
79 | *** |
80 | *** |
81 | **** |
Claims (13)
- 하기 화학식 I로 표시되는 화합물, 용매화물, 입체이성질체 또는 이의 약제학적으로 허용가능한 염.<화학식 I>상기 식에서,X, Y는 CR1R2 또는 NR3이고;R1, R2 또는 R3은 서로 같거나 상이하고, 각각 독립적으로 Ra-L-, Ra-L-CO-, Ra-L-NHCO-, Ra-L-OCO-, Ra-L-SO2-에서 선택되고;상기 Ra는 수소, 중수소, 시안, 할로겐, 나이트로, 할로알킬, 치환 또는 비치환된 C1-C10 직쇄 또는 분지된 알킬, 치환 또는 비치환된 C3-C8 사이클로알킬, 치환 또는 비치환된 C5-C20 아릴, 또는 치환 또는 비치환된 C5-C20 헤테로아릴 중에서 선택되며, 상기 헤테로아릴은 O, N, S 중 1, 2 또는 3개의 헤테로원자를 포함하고;상기 L은 직접 결합, C1-C5 알킬렌, 치환 또는 비치환된 C5-C10 아릴렌 중에서 선택되며;상기 R4는 수소 또는 치환 또는 비치환된 C1-C10 알킬 중에서 선택되며;A는 CR5 또는 N, B는 CR6 또는 N, D는 CR7 또는 N, E는 CR8 또는 N, G는 CR9 또는 N이고;상기 R5 내지 R9는 같거나 상이하고, 각각 독립적으로 수소, 중수소, 시안, 할로겐, 할로알킬, 카보닐, 나이트로, 카복실, C1-C5 알콕시, 치환 또는 비치환된 C1-C10 직쇄 또는 분지된 알킬, 치환 또는 비치환된 C3-C8 사이클로알킬, 치환 또는 비치환된 아민, 치환 또는 비치환된 C5-C20 아릴, 또는 치환 또는 비치환된 C5-C20 헤테로아릴 중에서 선택되고, 서로 인접하는 2 이상의 기는 서로 결합하여 치환 또는 비치환된 방향족 탄화수소 고리를 형성할 수 있고, 이때 방향족 탄화수소 고리는 N, O, S로부터 선택된 0, 1, 2 또는 3개의 헤테로원자를 포함하는 C5~C10의 헤테로아릴 고리 또는 아릴 고리를 형성할 수 있고;상기 치환된 C1-C10 직쇄 또는 분지된 알킬은 임의로 부분 불포화일 수 있고, 독립적으로 중수소, 할로겐, 시안, 나이트로, 카복실, 치환 또는 비치환된 아민, 치환 또는 비치환된 C5-C20 아릴 또는 C5-C20 헤테로아릴, 치환 또는 비치환된 C3-C8 사이클로알킬에서 선택되는 1개 이상의 치환기로 치환될 수 있고;상기 치환된 C3-C8 사이클로알킬은 독립적으로 중수소, 할로겐, 시안, 나이트로, 카복실, 치환 또는 비치환된 아민, 치환 또는 비치환된 C5-C20 아릴 또는 C5-C20 헤테로아릴, C1-C5 알콕시, C1-C5 할로알킬에서 선택되는 1개 이상의 치환기 또는 같거나 상이한 2 이상의 치환기가 연결되어 치환될 수 있고;상기 치환된 C5-C20 아릴 또는 치환된 C5-C20 헤테로아릴은 독립적으로 중수소, 할로겐, 시안, 나이트로, 카복실, 치환 또는 비치환된 아민, C1-C5 알콕시, C1-C5 할로알킬, C1-C10 알킬, C3-C8 사이클로알킬 C1-C10 알킬, C5-C20 아릴 C1-C10 알킬에서 선택되는 1개 이상의 치환기 또는 같거나 상이한 2 이상의 치환기가 연결되어 치환될 수 있고;상기 치환된 아민은 하나 또는 둘의 C1-C5 알킬기로 치환될 수 있고;상기 치환된 C5-C10 아릴렌은 C1-C3 알킬, 할로겐, 시안, 아민, 나이트로, 중수소 중에서 선택되는 1개 이상의 치환기 또는 같거나 상이한 2 이상의 치환기가 연결되어 치환될 수 있다.
- 제1항에 있어서,상기 화학식 I은 하기 화학식 I-1인 것을 특징으로 하는 화합물, 용매화물, 입체이성질체 또는 이의 약제학적으로 허용가능한 염<화학식 I-1>상기 식에서,X는 NR3이고,R3는 Ra-L-, Ra-L-CO-, Ra-L-NHCO-, Ra-L-OCO-, Ra-L-SO2-에서 선택되고;상기 Ra는 수소, 중수소, 시안, 할로겐, 나이트로, 할로알킬, 치환 또는 비치환된 C1-C10 직쇄 또는 분지된 알킬, 치환 또는 비치환된 C3-C8 사이클로알킬, 치환 또는 비치환된 C5-C20 아릴, 또는 치환 또는 비치환된 C5-C20 헤테로아릴 중에서 선택되며, 상기 헤테로아릴은 O, N, S 중 1, 2 또는 3개의 헤테로원자를 포함하고;상기 L은 직접 결합, C1-C5 알킬렌, 치환 또는 비치환된 C5-C10 아릴렌 중에서 선택되며;상기 R4는 수소 또는 치환 또는 비치환된 C1-C10 알킬 중에서 선택되며;A는 CR5 또는 N, B는 CR6 또는 N, D는 CR7 또는 N, E는 CR8 또는 N, G는 CR9 또는 N이고;상기 R5 내지 R9는 같거나 상이하고, 각각 독립적으로 수소, 중수소, 시안, 할로겐, 할로알킬, 카보닐, 나이트로, 카복실, C1-C5 알콕시, 치환 또는 비치환된 C1-C10 직쇄 또는 분지된 알킬, 치환 또는 비치환된 C3-C8 사이클로알킬, 치환 또는 비치환된 아민, 치환 또는 비치환된 C5-C20 아릴, 또는 치환 또는 비치환된 C5-C20 헤테로아릴 중에서 선택되고, 서로 인접하는 2 이상의 기는 서로 결합하여 치환 또는 비치환된 방향족 탄화수소 고리를 형성할 수 있고, 이때 방향족 탄화수소 고리는 N, O, S로부터 선택된 0, 1, 2 또는 3개의 헤테로원자를 포함하는 C5~C10의 헤테로아릴 고리 또는 아릴 고리를 형성할 수 있고;상기 치환된 C1-C10 직쇄 또는 분지된 알킬은 임의로 부분 불포화일 수 있고, 독립적으로 중수소, 할로겐, 시안, 나이트로, 카복실, 치환 또는 비치환된 아민, 치환 또는 비치환된 C5-C20 아릴 또는 C5-C20 헤테로아릴, 치환 또는 비치환된 C3-C8 사이클로알킬에서 선택되는 1개 이상의 치환기로 치환될 수 있고;상기 치환된 C3-C8 사이클로알킬은 독립적으로 중수소, 할로겐, 시안, 나이트로, 카복실, 치환 또는 비치환된 아민, 치환 또는 비치환된 C5-C20 아릴 또는 C5-C20 헤테로아릴, C1-C5 알콕시, C1-C5 할로알킬에서 선택되는 1개 이상의 치환기 또는 같거나 상이한 2 이상의 치환기가 연결되어 치환될 수 있고;상기 치환된 C5-C20 아릴 또는 치환된 C5-C20 헤테로아릴은 독립적으로 중수소, 할로겐, 시안, 나이트로, 카복실, 치환 또는 비치환된 아민, C1-C5 알콕시, C1-C5 할로알킬, C1-C10 알킬, C3-C8 사이클로알킬 C1-C10 알킬, C5-C20 아릴 C1-C10 알킬에서 선택되는 1개 이상의 치환기 또는 같거나 상이한 2 이상의 치환기가 연결되어 치환될 수 있고;상기 치환된 아민은 하나 또는 둘의 C1-C5 알킬기로 치환될 수 있고;상기 치환된 C5-C10 아릴렌은 C1-C3 알킬, 할로겐, 시안, 아민, 나이트로, 중수소 중에서 선택되는 1개 이상의 치환기 또는 같거나 상이한 2 이상의 치환기가 연결되어 치환될 수 있다.
- 제1항에 있어서,상기 화학식 I은 하기 화학식 I-2인 것을 특징으로 하는 화합물, 용매화물, 입체이성질체 또는 이의 약제학적으로 허용가능한 염.<화학식 I-2>상기 식에서,Y는 NR3이고,R3는 Ra-L-, Ra-L-CO-, Ra-L-NHCO-, Ra-L-OCO-, Ra-L-SO2-에서 선택되고;상기 Ra는 수소, 중수소, 시안, 할로겐, 나이트로, 할로알킬, 치환 또는 비치환된 C1-C10 직쇄 또는 분지된 알킬, 치환 또는 비치환된 C3-C8 사이클로알킬, 치환 또는 비치환된 C5-C20 아릴, 또는 치환 또는 비치환된 C5-C20 헤테로아릴 중에서 선택되며, 상기 헤테로아릴은 O, N, S 중 1, 2 또는 3개의 헤테로원자를 포함하고;상기 L은 직접 결합, C1-C5 알킬렌, 치환 또는 비치환된 C5-C10 아릴렌 중에서 선택되며;상기 R4는 수소 또는 치환 또는 비치환된 C1-C10 알킬 중에서 선택되며;A는 CR5 또는 N, B는 CR6 또는 N, D는 CR7 또는 N, E는 CR8 또는 N, G는 CR9 또는 N이고;상기 R5 내지 R9는 같거나 상이하고, 각각 독립적으로 수소, 중수소, 시안, 할로겐, 할로알킬, 카보닐, 나이트로, 카복실, C1-C5 알콕시, 치환 또는 비치환된 C1-C10 직쇄 또는 분지된 알킬, 치환 또는 비치환된 C3-C8 사이클로알킬, 치환 또는 비치환된 아민, 치환 또는 비치환된 C5-C20 아릴, 또는 치환 또는 비치환된 C5-C20 헤테로아릴 중에서 선택되고, 서로 인접하는 2 이상의 기는 서로 결합하여 치환 또는 비치환된 방향족 탄화수소 고리를 형성할 수 있고, 이때 방향족 탄화수소 고리는 N, O, S로부터 선택된 0, 1, 2 또는 3개의 헤테로원자를 포함하는 C5~C10의 헤테로아릴 고리 또는 아릴 고리를 형성할 수 있고;상기 치환된 C1-C10 직쇄 또는 분지된 알킬은 임의로 부분 불포화일 수 있고, 독립적으로 중수소, 할로겐, 시안, 나이트로, 카복실, 치환 또는 비치환된 아민, 치환 또는 비치환된 C5-C20 아릴 또는 C5-C20 헤테로아릴, 치환 또는 비치환된 C3-C8 사이클로알킬에서 선택되는 1개 이상의 치환기로 치환될 수 있고;상기 치환된 C3-C8 사이클로알킬은 독립적으로 중수소, 할로겐, 시안, 나이트로, 카복실, 치환 또는 비치환된 아민, 치환 또는 비치환된 C5-C20 아릴 또는 C5-C20 헤테로아릴, C1-C5 알콕시, C1-C5 할로알킬에서 선택되는 1개 이상의 치환기 또는 같거나 상이한 2 이상의 치환기가 연결되어 치환될 수 있고;상기 치환된 C5-C20 아릴 또는 치환된 C5-C20 헤테로아릴은 독립적으로 중수소, 할로겐, 시안, 나이트로, 카복실, 치환 또는 비치환된 아민, C1-C5 알콕시, C1-C5 할로알킬, C1-C10 알킬, C3-C8 사이클로알킬 C1-C10 알킬, C5-C20 아릴 C1-C10 알킬에서 선택되는 1개 이상의 치환기 또는 같거나 상이한 2 이상의 치환기가 연결되어 치환될 수 있고;상기 치환된 아민은 하나 또는 둘의 C1-C5 알킬기로 치환될 수 있고;상기 치환된 C5-C10 아릴렌은 C1-C3 알킬, 할로겐, 시안, 아민, 나이트로, 중수소 중에서 선택되는 1개 이상의 치환기 또는 같거나 상이한 2 이상의 치환기가 연결되어 치환될 수 있다.
- 제2항 또는 제3항에 있어서,상기 R3는 Ra-L-이고,L은 직접 결합, C1-C3 알킬렌 중에서 선택되고,A, B, D, E, G 중 N은 0 또는 1개이고,상기 R5 내지 R9는 같거나 상이하고, 각각 독립적으로 수소, 중수소, 시안, 할로겐, 할로알킬, 카보닐, 나이트로, 카복실, C1-C5 알콕시, C1-C5 알킬, 하나 이상의 할로겐 치환된 C1-C5 할로알킬, 치환 또는 비치환된 C3-C8 사이클로알킬, 치환 또는 비치환된 아민, 치환 또는 비치환된 C5-C10 아릴, 또는 치환 또는 비치환된 C5-C10 헤테로아릴 중에서 선택되고, 서로 인접하는 2 이상의 기는 서로 결합하여 치환 또는 비치환된 방향족 탄화수소 고리를 형성할 수 있고, 이때 방향족 탄화수소 고리는 N, O, S로부터 선택된 0, 1, 2 또는 3개의 헤테로원자를 포함하는 C5~C10의 헤테로아릴 고리 또는 아릴 고리를 형성할 수 있고;R4는 수소 또는 치환 또는 비치환된 C1-C5 알킬 중에서 선택되는 것인 화합물 또는 용매화물, 입체이성질체 또는 이의 약제학적으로 허용가능한 염.
- 제2항 또는 제3항에 있어서,상기 R3는 Ra-L-CO-이고;L은 직접 결합, C1-C3 알킬렌, 치환된 페닐렌 중에서 선택되고;A, B, D, E, G 중 N은 0 또는 1개이고;상기 R5 내지 R9는 같거나 상이하고, 각각 독립적으로 수소, 중수소, 시안, 할로겐, 할로알킬, 카보닐, 나이트로, 카복실, C1-C5 알콕시, C1-C5 알킬, 하나 이상의 할로겐 치환된 C1-C5 할로알킬, 치환 또는 비치환된 C3-C8 사이클로알킬, 치환 또는 비치환된 아민, 치환 또는 비치환된 C5-C10 아릴, 또는 치환 또는 비치환된 C5-C10 헤테로아릴 중에서 선택되고, 서로 인접하는 2 이상의 기는 서로 결합하여 치환 또는 비치환된 방향족 탄화수소 고리를 형성할 수 있고, 이때 방향족 탄화수소 고리는 N, O, S로부터 선택된 0, 1, 2 또는 3개의 헤테로원자를 포함하는 C5~C10의 헤테로아릴 고리 또는 아릴 고리를 형성할 수 있고;R4는 치환 또는 비치환된 C1-C5 알킬 중에서 선택되는 것수소 또는인 화합물 또는 용매화물, 입체이성질체 또는 이의 약제학적으로 허용가능한 염.
- 제2항 또는 제3항에 있어서;상기 R3는 Ra-L-NHCO-이고L은 직접 결합, C1-C3 알킬렌 중에서 선택되고;A, B, D, E, G 중 N은 0 또는 1이고;상기 R5 내지 R9는 같거나 상이하고, 각각 독립적으로 수소, 중수소, 시안, 할로겐, 할로알킬, 카보닐, 나이트로, 카복실, C1-C5 알콕시, C1-C5 알킬, 하나 이상의 할로겐 치환된 C1-C5 할로알킬, 치환 또는 비치환된 C3-C8 사이클로알킬, 치환 또는 비치환된 아민, 치환 또는 비치환된 C5-C10 아릴, 또는 치환 또는 비치환된 C5-C10 헤테로아릴 중에서 선택되고, 서로 인접하는 2 이상의 기는 서로 결합하여 치환 또는 비치환된 방향족 탄화수소 고리를 형성할 수 있고, 이때 방향족 탄화수소 고리는 N, O, S로부터 선택된 0, 1, 2 또는 3개의 헤테로원자를 포함하는 C5~C10의 헤테로아릴 고리 또는 아릴 고리를 형성할 수 있고;R4는 수소 또는 치환 또는 비치환된 C1-C5 알킬 중에서 선택되는 것인 화합물 또는 용매화물, 입체이성질체 또는 이의 약제학적으로 허용가능한 염.
- 제2항 또는 제3항에 있어서,상기 R3는 Ra-L-OCO-이고;L은 직접 결합, C1-C3 알킬렌 중에서 선택되고;A, B, D, E, G 중 N은 0 또는 1이고;상기 R5 내지 R9는 같거나 상이하고, 각각 독립적으로 수소, 중수소, 시안, 할로겐, 할로알킬, 카보닐, 나이트로, 카복실, C1-C5 알콕시, C1-C5 알킬, 하나 이상의 할로겐 치환된 C1-C5 할로알킬, 치환 또는 비치환된 C3-C8 사이클로알킬, 치환 또는 비치환된 아민, 치환 또는 비치환된 C5-C10 아릴, 또는 치환 또는 비치환된 C5-C10 헤테로아릴 중에서 선택되고, 서로 인접하는 2 이상의 기는 서로 결합하여 치환 또는 비치환된 방향족 탄화수소 고리를 형성할 수 있고, 이때 방향족 탄화수소 고리는 N, O, S로부터 선택된 0, 1, 2 또는 3개의 헤테로원자를 포함하는 C5~C10의 헤테로아릴 고리 또는 아릴 고리를 형성할 수 있고;R4는 수소 또는 치환 또는 비치환된 C1-C5 알킬 중에서 선택되는 것인 화합물 또는 용매화물, 입체이성질체 또는 이의 약제학적으로 허용가능한 염.
- 제2항 또는 제3항에 있어서,상기 R3는 Ra-L-SO2-이고;L은 직접 결합, C1-C3 알킬렌 중에서 선택되고;A, B, D, E, G 중 N은 0 또는 1이고;상기 R5 내지 R9는 같거나 상이하고, 각각 독립적으로 수소, 중수소, 시안, 할로겐, 할로알킬, 카보닐, 나이트로, 카복실, C1-C5 알콕시, C1-C5 알킬, 하나 이상의 할로겐 치환된 C1-C5 할로알킬, 치환 또는 비치환된 C3-C8 사이클로알킬, 치환 또는 비치환된 아민, 치환 또는 비치환된 C5-C10 아릴, 또는 치환 또는 비치환된 C5-C10 헤테로아릴 중에서 선택되고, 서로 인접하는 2 이상의 기는 서로 결합하여 치환 또는 비치환된 방향족 탄화수소 고리를 형성할 수 있고, 이때 방향족 탄화수소 고리는 N, O, S로부터 선택된 0, 1, 2 또는 3개의 헤테로원자를 포함하는 C5~C10의 헤테로아릴 고리 또는 아릴 고리를 형성할 수 있고;R4는 수소 또는 치환 또는 비치환된 C1-C5 알킬 중에서 선택되는 것인 화합물 또는 용매화물, 입체이성질체 또는 이의 약제학적으로 허용가능한 염.
- 제1항에 있어서,상기 화학식 I로 표시되는 화합물은 하기 화합물로부터 선택되는 것으로 특징으로 하는 화학식 I로 표시되는 화합물 또는 이의 염.2-(피리딘-2-일)-4,5,6,7-테트라하이드로-2H-인다졸-3-올;2-(5-(트리플루오로메틸)피리딘-2-일)-4,5,6,7-테트라하이드로-2H-인다졸-3-올;6-벤질-2-(피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올;6-벤질-2-(피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올;6-벤질-2-(5-(트리플루오로메틸)피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올;6-(4-플루오로벤질)-2-(피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올;6-(4-메틸벤질)-2-(피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올;4-((3-하이드록시-2-(피리딘-2-일)-2,4,5,7-테트라하이드로-6H-피라졸로[3,4-c]피리딘-6-일)메틸)벤조나이트릴;6-(3,5-다이플루오로벤질)-2-(피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올;2-(피리딘-2-일)-6-(3-(트리플루오로메틸)벤질)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올;6-(나프탈렌-2-일메틸)-2-(피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올;1-(4,5-다이하이드로-3-하이드록시-2-(피리딘-2-일)-2H-피라졸로[3,4-c]피리딘-6(7H)-일)부탄-1-온;1-(3-하이드록시-2-(피리딘-2-일)-2,4,5,7-테트라하이드로-6H-피라졸로[3,4-c]피리딘-6-일)에탄-1-온;6-(4-메톡시벤질)-2-(피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올;6-에틸-2-(피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올;6-(프로프-2-인-1-일)-2(피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올;6-프로필-2-(피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올;6-알릴-2-(피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올;(3-하이드록시-2-(피리딘-2-일)-2,4,5,7-테트라하이드로-6H-피라졸로[3,4-c]피리딘-6-일)(페닐)메타논;벤질 3-하이드록시-2-(피리딘-2-일)-2,4,5,7-테트라하이드로-6H-피라졸로[3,4-c]피리딘-6-카복실레이트;(4-클로로페닐)(3-하이드록시-2-(피리딘-2-일)-2,4,5,7-테트라하이드로-6H-피라졸로[3,4-c]피리딘-5-일)메타논;에틸 3-하이드록시-2-(피리딘-2-일)-2,4,5,7-테트라하이드로-6H-피라졸로[3,4-c]피리딘-6-카복실레이트;N-사이클로헥실-3-하이드록시-2-(피리딘-2-일)-2,4,5,7-테트라하이드로-6H-피라졸로[3,4-c]피리딘-6-카복사마이드;퓨란-2-일(3-하이드록시-2-(피리딘-2-일)-2,4,5,7-테트라하이드로-6H-피라졸로[3,4-c]피리딘-6-일)메타논;6-(메틸술포닐)-2-(피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올;6-(페닐술포닐)-2-(피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올;N-(4-플루오로페닐)-3-하이드록시-2-(피리딘-2-일)-2,4,5,7-테트라하이드로-6H-피라졸로[3,4-c]피리딘-6-카복사마이드;N-(4-플루오로벤질)-3-하이드록시-2-(피리딘-2-일)-2,4,5,7-테트라하이드로-6H-피라졸로[3,4-c]피리딘-6-카복사마이드;N-(퓨란-2-일메틸)-3-하이드록시-2-(피리딘-2-일)-2,4,5,7-테트라하이드로-6H-피라졸로[3,4-c]피리딘-6-카복사마이드;N-(4-클로로페네틸)-3-하이드록시-2-(피리딘-2-일)-2,4,5,7-테트라하이드로-6H-피라졸로[3,4-c]피리딘-6-카복사마이드;6-(나프탈렌-2-일술포닐)-2-(피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올;4-나이트로벤질 3-하이드록시-2-(피리딘-2-일)-2,4,5,7-테트라하이드로-6H-피라졸로[3,4-c]피리딘-6-카복실레이트;(5-(4-사이클로프로필-1H-이미다졸-1-일)-2-플루오로-4-메틸페닐)(3-하이드록시-2-(피리딘-2-일)-2,4,5,7-테트라하이드로-6H-피라졸로[3,4-c]피리딘-6-일)메타논;5-벤질-2-(피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[4,3-c]피리딘-3-올;6-벤질-2-(5-클로로피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올;4-(6-벤질-3-하이드록시-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-2-일)벤조산;6-벤질-2-(4-브로모페닐)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올;6-벤질-2-페닐-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올;5-벤질-2-(5-트리플루오로메틸)피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[4,3-c]피리딘-3-올;5-벤질-2-페닐-4,5,6,7-테트라하이드로-2H-피라졸로[4,3-c]피리딘-3-올;5-벤질-2-(4-브로모페닐)-4,5,6,7-테트라하이드로-2H-피라졸로[4,3-c]피리딘-3-올;5-벤질-2-(2-클로로페닐)-4,5,6,7-테트라하이드로-2H-피라졸로[4,3-c]피리딘-3-올;6-벤질-2-(2-클로로페닐)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올;6-벤질-2-(2-메톡시페닐)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올;5-벤질-2-(5-클로로피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[4,3-c]피리딘-3-올;5-벤질-2-(6-메틸-4-(트리플루오로메틸)피리딘-2-일)- 4,5,6,7-테트라하이드로-2H-피라졸로[4,3-c]피리딘-3-올;5-벤질-2-(티에노[3,2-c]피리딘-4-일)-4,5,6,7-테트라하이드로-2H-피라졸로[4,3-c]피리딘-3-올;5-(나프탈렌-2-일메틸)-2-(피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[4,3-c]피리딘-3-올;5-(나프탈렌-2-일메틸)-2-(5-(트리플루오로메틸)피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[4,3-c]피리딘-3-올;5-(3-(트리플루오로메틸)벤질)-2-(5-(트리플루오로메틸)피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[4,3-c]피리딘-3-올;5-(3,5-다이플루오로벤질)-2-(피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[4,3-c]피리딘-3-올;5-(3,5-다이플루오로벤질)-2-(5-트리플루오로메틸)피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[4,3-c]피리딘-3-올;6-벤질-3-메톡시-2-(피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘;6-(6-벤질-3-하이드록시-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-2-일)니코티노나이트릴;6-벤질-2-(6-(트리플루오로메틸)피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올;6-벤질-2-(3-플루오로피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올;6-벤질-2-(6-메틸피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올;6-벤질-2-(6-메틸-4-(트리플루오로메틸)피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올;5-벤질-2-(6-메틸피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[4,3-c]피리딘-3-올;5-벤질-2-(6-트리플루오로메틸)피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[4,3-c]피리딘-3-올;6-(5-벤질-3-하이드록시-4,5,6,7-테트라하이드로-2H-피라졸로[4,3-c]피리딘-2-일)니코티노나이트릴;5-벤질-2-(3-플루오로피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[4,3-c]피리딘-3-올;5-벤질-2-(티에노[3,2-c]피리딘-4-일)-4,5,6,7-테트라하이드로-2H-피라졸로[4,3-c]피리딘-3-올;5-벤질-2-(6-메틸-4-(트리플루오로메틸)피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[4,3-c]피리딘-3-올;6-벤질-2-(티에노[3,2-c]피리딘-4-일)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올;2-(피리딘-2-일)-6-(피리딘-2-일메틸)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올;2-(피리딘-2-일)-6-(피리딘-4-일메틸)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올;6-(4-(다이메틸아미노)벤질)-2-(피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올;6-(3-(다이메틸아미노)벤질)-2-(피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올;2-(6-아미노피리딘-2-일)-6-벤질-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올;5-(4-(다이메틸아미노)벤질)-2-(피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[4,3-c]피리딘-3-올;5-(3-(다이메틸아미노)벤질)-2-(피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[4,3-c]피리딘-3-올;2-(피리딘-2-일)-6-(퀴놀린-6-일메틸)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올;6-(이소퀴놀린-3-일메틸)-2-(피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[3,4-c]피리딘-3-올;4-((3-하이드록시-2-(피리딘-2-일)-2,4,6,7-테트라하이드로-5H-피라졸로[4,3-c]피리딘-5-일)메틸)벤조나이트릴;4-((3-하이드록시-2-(5-(트리플루오로메틸)피리딘-2-일)-2,4,6,7-테트라하이드로-5H-피라졸로[4,3-c]피리딘-5-일)메틸)벤조나이트릴;2-(피리딘-2-일)-5-(3-(트리플루오로메틸)벤질)-4,5,6,7-테트라하이드로-2H-피라졸로[4,3-c]피리딘-3-올;5-(3-(트리플루오로메틸)벤질)-2-(5-(트리플루오로메틸)피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[4,3-c]피리딘-3-올;5-(이소퀴놀린-3-일메틸)-2-(피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[4,3-c]피리딘-3-올;5-(이소퀴놀린-3-일메틸)-2-(5-(트리플루오로메틸)피리딘-2-일)-4,5,6,7-테트라하이드로-2H-피라졸로[4,3-c]피리딘-3-올;4-(5-벤질-3-하이드록시-4,5,6,7-테트라하이드로-2H-피라졸로[4,3-c]피리딘-2-일)벤조산.
- 제 1항에 있어서,상기 염은 염산, 브롬화수소산, 황산, 인산, 질산, 아세트산, 글리콜산, 락트산, 피루브산, 말론산, 석신산, 글루타르산, 푸마르산, 말산, 만델산, 타르타르산, 시트르산, 아스코르브산, 팔미트산, 말레산, 벤조산, 하이드록시벤조산, 페닐아세트산, 신남산, 살리실산, 메탄설폰산, 에탄설폰살, 벤젠설폰산 및 톨루엔설폰산 등으로 이루어진 군으로부터 선택되는 1종 이상의 산에 의해 유도된 염 형태인 것을 특징으로 하는 화합물 또는 이의 염.
- 유효성분으로서 제1항 내지 제3항 중 어느 한 항의 화합물 또는 이의 약제학적으로 허용가능한 염 및 약제학적으로 허용가능한 담체를 포함하는 산화성 스트레스와 관련된 질환을 예방 또는 치료하기 위한 약제학적 조성물.
- 제11항에 있어서,상기 약제학적으로 허용가능한 담체는 부형제, 희석제, 붕해제, 결합제, 활택제, 계면활성제, 유화제, 현탁제, 및 희석제로 이루어진 군으로부터 선택되는 1종 이상인 것을 특징으로 하는 약제학적 조성물.
- 제11항에 있어서,상기 산화성 스트레스와 관련된 질환은 암, 켈로이드증, 간섬유화증, 간경화증, 폐섬유화증. 파킨슨병, 헌팅턴병, 근위축성 측상 경화증, 다발성 경화증, 허혈성 또는 외상성 뇌 손상, 망막섬유화중, 황반변성, 염증성 질환에서 선택된 것을 특징으로 하는 약제학적 조성물.
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2022008665A MX2022008665A (es) | 2020-01-13 | 2021-01-12 | Nuevo derivado de pirazol. |
IL294674A IL294674A (en) | 2020-01-13 | 2021-01-12 | Pirzol derivative |
BR112022013849A BR112022013849A2 (pt) | 2020-01-13 | 2021-01-12 | Novo derivado de pirazol |
AU2021208915A AU2021208915B2 (en) | 2020-01-13 | 2021-01-12 | Novel pyrazole derivative |
CN202180009272.6A CN114945561A (zh) | 2020-01-13 | 2021-01-12 | 新吡唑衍生物 |
US17/791,983 US20230067461A1 (en) | 2020-01-13 | 2021-01-12 | Novel pyrazole derivative |
EP21740932.5A EP4105206A1 (en) | 2020-01-13 | 2021-01-12 | Novel pyrazole derivative |
JP2022543171A JP2023511302A (ja) | 2020-01-13 | 2021-01-12 | 新規なピラゾール誘導体 |
CA3167675A CA3167675A1 (en) | 2020-01-13 | 2021-01-12 | Pyrazole derivatives |
CONC2022/0010431A CO2022010431A2 (es) | 2020-01-13 | 2022-07-26 | Nuevo derivado de pirazol |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20200004471 | 2020-01-13 | ||
KR10-2020-0004471 | 2020-01-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021145655A1 true WO2021145655A1 (ko) | 2021-07-22 |
Family
ID=76864348
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/000425 WO2021145655A1 (ko) | 2020-01-13 | 2021-01-12 | 신규한 피라졸 유도체 |
Country Status (13)
Country | Link |
---|---|
US (1) | US20230067461A1 (ko) |
EP (1) | EP4105206A1 (ko) |
JP (1) | JP2023511302A (ko) |
KR (1) | KR102333863B1 (ko) |
CN (1) | CN114945561A (ko) |
AU (1) | AU2021208915B2 (ko) |
BR (1) | BR112022013849A2 (ko) |
CA (1) | CA3167675A1 (ko) |
CL (1) | CL2022001888A1 (ko) |
CO (1) | CO2022010431A2 (ko) |
IL (1) | IL294674A (ko) |
MX (1) | MX2022008665A (ko) |
WO (1) | WO2021145655A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115916766A (zh) * | 2021-02-25 | 2023-04-04 | 阿普塔生物治疗公司 | 新型吡唑衍生物 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023191201A1 (ko) * | 2022-03-31 | 2023-10-05 | 압타바이오 주식회사 | 신규한 피라졸 유도체 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2701467A1 (de) * | 1976-01-16 | 1977-07-28 | Du Pont | Substituierte cycloalkanapyrazole, sie enthaltende herbizide und verfahren zur kontrolle von unerwuenschter vegetation |
KR20060054291A (ko) * | 2003-07-10 | 2006-05-22 | 아방티 파르마 소시에테 아노님 | 치환된 테트라하이드로-1H-피라졸로[3,4-c]피리딘, 이를 함유하는 조성물 및 이의 용도 |
WO2010015657A2 (en) * | 2008-08-05 | 2010-02-11 | Institut Pasteur | New alkoxypyrazoles |
WO2011101804A1 (en) * | 2010-02-18 | 2011-08-25 | Genkyotex Sa | Pyrazolo piperidine derivatives as nadph oxidase inhibitors |
KR20140015156A (ko) * | 2009-12-14 | 2014-02-06 | 사노피 | 신규 (헤테로사이클/축합된 피페리딘)-(피페라지닐)-1-알카논 또는 (헤테로사이클/축합된 피롤리딘)-(피페라지닐)-1-알카논 유도체, 및 p75 억제제로서의 그의 용도 |
US20140275015A1 (en) * | 2013-03-14 | 2014-09-18 | Janssen Pharmaceutica Nv | P2x7 modulators |
WO2015144801A1 (en) | 2014-03-27 | 2015-10-01 | Janssen Pharmaceutica Nv | SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AND 2,3-DIHYDRO-1H-IMIDAZO[1,2-b]PYRAZOLE DERIVATIVES AS ROS1 INHIBITORS |
WO2016207785A1 (en) | 2015-06-22 | 2016-12-29 | Actelion Pharmaceuticals Ltd | Nadph oxidase 4 inhibitors |
KR20200004471A (ko) | 2015-09-28 | 2020-01-13 | 가부시키가이샤 스크린 홀딩스 | 기판 처리 방법 및 기판 처리 장치 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9708334B2 (en) * | 2014-04-24 | 2017-07-18 | Dart Neuroscience (Cayman) Ltd. | Substituted 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine compounds as GlyT1 inhibitors |
WO2019141957A1 (en) * | 2018-01-19 | 2019-07-25 | Cado Biotechnology Ivs | N-pyrimidinyl hydroxy pyrazole derivatives and uses thereof |
-
2021
- 2021-01-12 MX MX2022008665A patent/MX2022008665A/es unknown
- 2021-01-12 CA CA3167675A patent/CA3167675A1/en active Pending
- 2021-01-12 US US17/791,983 patent/US20230067461A1/en active Pending
- 2021-01-12 KR KR1020210004079A patent/KR102333863B1/ko active IP Right Grant
- 2021-01-12 IL IL294674A patent/IL294674A/en unknown
- 2021-01-12 JP JP2022543171A patent/JP2023511302A/ja active Pending
- 2021-01-12 WO PCT/KR2021/000425 patent/WO2021145655A1/ko unknown
- 2021-01-12 EP EP21740932.5A patent/EP4105206A1/en active Pending
- 2021-01-12 BR BR112022013849A patent/BR112022013849A2/pt not_active Application Discontinuation
- 2021-01-12 AU AU2021208915A patent/AU2021208915B2/en active Active
- 2021-01-12 CN CN202180009272.6A patent/CN114945561A/zh active Pending
-
2022
- 2022-07-12 CL CL2022001888A patent/CL2022001888A1/es unknown
- 2022-07-26 CO CONC2022/0010431A patent/CO2022010431A2/es unknown
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2701467A1 (de) * | 1976-01-16 | 1977-07-28 | Du Pont | Substituierte cycloalkanapyrazole, sie enthaltende herbizide und verfahren zur kontrolle von unerwuenschter vegetation |
KR20060054291A (ko) * | 2003-07-10 | 2006-05-22 | 아방티 파르마 소시에테 아노님 | 치환된 테트라하이드로-1H-피라졸로[3,4-c]피리딘, 이를 함유하는 조성물 및 이의 용도 |
WO2010015657A2 (en) * | 2008-08-05 | 2010-02-11 | Institut Pasteur | New alkoxypyrazoles |
KR20140015156A (ko) * | 2009-12-14 | 2014-02-06 | 사노피 | 신규 (헤테로사이클/축합된 피페리딘)-(피페라지닐)-1-알카논 또는 (헤테로사이클/축합된 피롤리딘)-(피페라지닐)-1-알카논 유도체, 및 p75 억제제로서의 그의 용도 |
WO2011101804A1 (en) * | 2010-02-18 | 2011-08-25 | Genkyotex Sa | Pyrazolo piperidine derivatives as nadph oxidase inhibitors |
US20140275015A1 (en) * | 2013-03-14 | 2014-09-18 | Janssen Pharmaceutica Nv | P2x7 modulators |
WO2015144801A1 (en) | 2014-03-27 | 2015-10-01 | Janssen Pharmaceutica Nv | SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AND 2,3-DIHYDRO-1H-IMIDAZO[1,2-b]PYRAZOLE DERIVATIVES AS ROS1 INHIBITORS |
WO2016207785A1 (en) | 2015-06-22 | 2016-12-29 | Actelion Pharmaceuticals Ltd | Nadph oxidase 4 inhibitors |
KR20200004471A (ko) | 2015-09-28 | 2020-01-13 | 가부시키가이샤 스크린 홀딩스 | 기판 처리 방법 및 기판 처리 장치 |
Non-Patent Citations (5)
Title |
---|
ALESSANDRO G. FOISPANAGIOTIS PALIGIANNIS ET AL., RESPIR RES, vol. 19, 2018, pages 51 |
LAN TKISSELEVA TBRENNER DA, PLOS ONE, vol. 10, 2015, pages e0129743 |
MENGJIA SONGXINFENG CHEN ET AL., CHINESE JOURNAL OF CANCER RESEARCH, vol. 30, no. 2, 2018, pages 157 - 172 |
MERRY W. MAJIN WANG ET AL., MOLECULAR NEURODEGENERATION, vol. 12, 2017, pages 7 |
ROHAN SAMARAKOONJESSICA M. OVERSTREET ET AL., CELL SIGNAL, no. 1, 25 January 2013 (2013-01-25), pages 264 - 268 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115916766A (zh) * | 2021-02-25 | 2023-04-04 | 阿普塔生物治疗公司 | 新型吡唑衍生物 |
Also Published As
Publication number | Publication date |
---|---|
MX2022008665A (es) | 2022-08-10 |
AU2021208915A1 (en) | 2022-09-01 |
KR102333863B1 (ko) | 2021-12-03 |
CN114945561A (zh) | 2022-08-26 |
US20230067461A1 (en) | 2023-03-02 |
BR112022013849A2 (pt) | 2022-09-13 |
CO2022010431A2 (es) | 2022-08-09 |
CA3167675A1 (en) | 2021-07-22 |
IL294674A (en) | 2022-09-01 |
JP2023511302A (ja) | 2023-03-17 |
EP4105206A1 (en) | 2022-12-21 |
CL2022001888A1 (es) | 2023-02-24 |
KR20210091063A (ko) | 2021-07-21 |
AU2021208915B2 (en) | 2024-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2016200101A2 (ko) | 트리사이클릭 유도체 화합물, 이의 제조방법 및 이를 포함하는 약학적 조성물 | |
WO2017188694A1 (ko) | 질소를 포함하는 헤테로아릴 화합물 및 이의 용도 | |
WO2021145655A1 (ko) | 신규한 피라졸 유도체 | |
WO2017142325A1 (ko) | 단백질 키나아제 저해제인 신규 2,3,5-치환된 싸이오펜 화합물 | |
WO2018139903A1 (ko) | 피리미딘 화합물 및 그의 의약 용도 | |
WO2018004213A1 (ko) | Smo 저해 활성을 갖는 신규 화합물 및 이를 유효성분으로 포함하는 암 예방 또는 치료용 조성물 | |
WO2012115479A2 (en) | Diaminopyrimidine derivatives and processes for the preparation thereof | |
WO2017176040A1 (ko) | Ras를 분해하는 이종원자고리화합물 및 이의 용도 | |
WO2018004065A1 (ko) | 신규한 아릴에텐 유도체 및 이를 유효성분으로 함유하는 약제학적 조성물 | |
WO2016108489A1 (ko) | 신규한 루테늄 화합물 및 이를 유효성분으로 함유하는 암 질환 예방 또는 치료용 약학 조성물 | |
WO2016006975A2 (en) | Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof | |
WO2016006974A2 (en) | Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof | |
WO2020096416A1 (ko) | Yap-tead 결합을 저해하는 화합물 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약제학적 조성물 | |
WO2022182205A1 (ko) | 신규한 피라졸 유도체 | |
WO2021096112A1 (ko) | 피롤로피리미딘, 피롤로피리딘, 인다졸 화합물 유도체 및 이를 포함하는 치료용 약학 조성물 | |
WO2018056621A1 (ko) | 신규한 이미다졸일 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 | |
WO2020013531A1 (ko) | N-(3-(이미다조[1,2-b]피리다진-3-일에티닐)-4-메틸페닐)-5-페닐-4,5-다이하이드로-1H-피라졸-1-카복사마이드 유도체 및 이를 유효성분으로 포함하는 키나아제 관련 질환 치료용 약학적 조성물 | |
WO2022103149A1 (ko) | 신규한 카바졸 유도체 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 | |
WO2021040502A1 (ko) | 이미다조피리딘 유도체 및 이를 유효성분으로 함유하는 약학적 조성물 | |
WO2021149900A1 (ko) | 이치환 아다만틸 유도체, 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 포함하는 암 성장 억제용 약학적 조성물 | |
WO2021235813A1 (ko) | Ron 돌연변이와 관련된 췌장암 예방 또는 치료용 약학 조성물 및 이를 이용한 방법 | |
WO2023191201A1 (ko) | 신규한 피라졸 유도체 | |
WO2017164705A1 (ko) | 신규한 피리딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 fgfr 관련 질환의 예방 또는 치료용 약학적 조성물 | |
EP3166945A2 (en) | Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof | |
WO2021137665A1 (ko) | Hsp90 억제제로서의 1,2,3-트리아졸 유도체 화합물 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21740932 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3167675 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2022543171 Country of ref document: JP Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022013849 Country of ref document: BR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021208915 Country of ref document: AU Date of ref document: 20210112 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2021740932 Country of ref document: EP Effective date: 20220816 |
|
ENP | Entry into the national phase |
Ref document number: 112022013849 Country of ref document: BR Kind code of ref document: A2 Effective date: 20220712 |